Chiropractic Practice: What to Know About Obesity Medicine

Learn how chiropractic practices integrate chiropractic care with obesity medicine to combat obesity and improve wellness.

Abstract: What This Educational Post Covers

I am Dr. Alex Jimenez, and in this comprehensive educational post, I walk you through one of the most clinically demanding and personally meaningful areas of my practice: the integrative, lifespan-focused management of obesity. I hold credentials as a Doctor of Chiropractic (DC), Advanced Practice Registered Nurse and Family Nurse Practitioner (APRN, FNP-BC), Certified Functional Medicine Practitioner (CFMP), Institute for Functional Medicine Certified Practitioner (IFMCP), Athletic Training Neuropathy Specialist (ATN), and Certified Chiropractic Sports Therapist (CCST). My clinical observations and educational resources are available at healthcoach. clinic and through my professional profile on LinkedIn.

This post represents the convergence of all the dimensions I work in daily at Injury Medical Clinic PA, also known as Mission Plaza Injury Medical Clinic, in El Paso, Texas. Together with our Medical Director and Collaborative Physician, Dr. Maria Guadalupe Cardenas, MD, who is Board Certified in Internal Medicine (NPI #1164426749, Texas MD License #J2933) and brings over 40 years of internist experience to our team, we have built a multidisciplinary integrative care model that treats obesity not as a cosmetic inconvenience or a failure of willpower but as a complex, chronic, relapsing, multifactorial disease that demands structured, compassionate, and scientifically rigorous long-term care.

The topics I cover in this post include:

• Why obesity must be understood and treated as a chronic disease, with the same intentionality and clinical infrastructure we bring to diabetes, hypertension, and cardiovascular disease
• The foundational physiology of obesity, including neuroendocrine signaling, adipose tissue biology, autonomic dysregulation, gut microbiome function, and chronic systemic inflammation
• The four core pillars of obesity treatment: nutrition therapy, physical activity and functional movement, behavioral counseling, and medical management including pharmacotherapy and surgical pathways
• How integrative chiropractic care fits within a comprehensive obesity treatment model by addressing musculoskeletal barriers to activity, modulating the autonomic nervous system, and enabling the physical capacity needed for lasting metabolic change
• The role of functional medicine in identifying and addressing root causes: insulin resistance, hormonal dysregulation, gut dysbiosis, nutritional deficiencies, toxic burden, and mitochondrial dysfunction
• Stigma-free, person-centered communication and the measurable physiological harm of weight stigma in clinical settings
• Stigma-free imaging resources and how the language and visuals we use in clinical environments either support or undermine patient outcomes
• The updated ICD-10 coding framework for obesity, including the October 2024 revisions, and the mandatory pairing of E codes and Z codes
• Primary versus secondary coding decisions and the reasoning behind them
• Time-based billing and Medical Decision-Making (MDM) under current CPT guidelines, with practical documentation templates
• Specialized billing pathways including Medicare’s Intensive Behavioral Therapy (IBT), preventive counseling codes for commercial insurance, Chronic Care Management (CCM), and Remote Patient Monitoring (RPM)
• How to build a six-month structured care plan that creates weekly patient touchpoints and supports long-term adherence
• Practice models, referral networks, scheduling frameworks, and hybrid telehealth-in-person care delivery
• The intersection of personal injury and obesity, including how trauma, inflammation, and metabolic dysfunction interact in patients recovering from accidents
• The social determinants of health and culturally competent obesity care, with specific attention to the diverse patient population we serve in El Paso, Texas
• Clinical scenarios illustrating how our integrative approach works in real patient care
• The evidence base anchoring every element of this framework, including findings from the Look AHEAD trial, the PREDIMED trial, the STEP and SURMOUNT trials, functional medicine research, and chiropractic clinical literature

This post is written for clinicians, nurse practitioners, chiropractors, functional medicine providers, billers, coders, and patients who want a deep, honest, and practically useful understanding of what modern obesity care actually requires. I have written every word from first-person clinical experience, shaped by decades of treating patients at the intersection of pain, metabolic disease, injury, and chronic illness in one of the most underserved border communities in the United States.

Why an Integrative, Lifespan Approach to Obesity Care Matters

I have been treating complex musculoskeletal and metabolic conditions for decades, and one truth has emerged with absolute clarity across every patient population I have served: obesity is not a temporary challenge, a phase to be corrected, or a reflection of insufficient discipline. It is a chronic, relapsing disease that requires the same long-term, adaptive, structured clinical thinking we bring to managing diabetes or heart failure. Like those conditions, obesity responds to deliberate follow-up, structured clinical pathways, and a clinical team willing to adapt care as the disease’s biology shifts over time.

At Injury Medical Clinic PA in El Paso, Texas, our patient population reflects the beautiful and complicated reality of a border community: patients presenting with overlapping pain, metabolic imbalance, sleep disruption, psychosocial stressors, personal injury complications, and socioeconomic barriers to care. These elements do not exist in isolation. Pain reduces physical activity; reduced activity worsens insulin resistance; disrupted sleep amplifies appetite dysregulation through hormonal mechanisms involving leptin and ghrelin; and the biology of chronic stress, mediated by the hypothalamic-pituitary-adrenal (HPA) axis and driven by elevated cortisol, literally rearranges where and how the body stores fat. A siloed approach, treating the back pain here, the blood sugar there, the weight somewhere else, fails these patients. Integration is the only humane and effective answer.

This post translates my clinical experience, my team’s collaborative practice, and the best available evidence into a first-person educational roadmap. I explain not just what we do, but why we do it, grounding every clinical decision in physiology, research, and the lived realities of patients too often failed by a healthcare system that treated their chronic disease as a personal failing.

Our Multidisciplinary Team: Medical Oversight, Chiropractic Care, and Functional Medicine Working Together

Dr. Maria Guadalupe Cardenas, MD: Medical Direction and Internal Medicine Expertise

Our integrative model begins with medical oversight. Dr. Maria Guadalupe Cardenas, MD, is Board Certified in Internal Medicine (NPI #1164426749, Texas MD License #J2933) and serves as our Medical Director and Collaborative Physician at Injury Medical Clinic PA. With over 40 years of experience as an internist, Dr. Cardenas brings irreplaceable clinical wisdom to a practice serving a population with high rates of comorbid chronic disease, socioeconomic vulnerability, and complex medical histories.

Her role is not ceremonial. Dr. Cardenas is the medical anchor of our team, responsible for:

• Comprehensive internal medicine evaluation, including assessment of cardiovascular risk, metabolic markers, endocrine function, and organ health across all organ systems
• Medication management for comorbid conditions including hypertension, type 2 diabetes mellitus, dyslipidemia, obstructive sleep apnea, and non-alcoholic fatty liver disease
• Diagnostic workup and laboratory interpretation, including advanced metabolic panels, inflammatory markers, hormone panels, and imaging studies
• Anti-obesity medication prescribing and management, including GLP-1 receptor agonists, dual GLP-1/GIP agonists, and other FDA-approved pharmacological agents
• Medical co-management of all patients undergoing chiropractic or functional medicine treatment, ensuring safety and seamless coordination
• Referral coordination for specialist services, including bariatric surgery evaluation, cardiology, endocrinology, sleep medicine, and hepatology
• Oversight of escalation pathways when patients require higher-acuity medical attention than our clinic can provide

With Dr. Cardenas’s internal medicine expertise as the medical foundation, I can deliver integrative chiropractic and functional medicine care with the confidence that complex medical decisions are made by someone who has spent four decades doing exactly that.

Dr. Alex Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST: Integrative Chiropractic, Advanced Practice Nursing, and Functional Medicine

My role at Injury Medical Clinic PA is to bridge structural health and systemic health. As a Doctor of Chiropractic, I address the musculoskeletal and neurological dimensions of chronic disease, recognizing that obesity, chronic pain, inflammation, and metabolic dysfunction are physiologically interwoven in ways that make treating any one of them in isolation clinically incomplete.

As an Advanced Practice Registered Nurse with Family Nurse Practitioner certification, I can order and interpret diagnostic tests, prescribe medications, conduct comprehensive patient assessments across the lifespan, and address the full spectrum of primary care needs within a collaborative framework. As a Certified Functional Medicine Practitioner (CFMP) and Institute for Functional Medicine Certified Practitioner (IFMCP), I apply a systems-biology approach that seeks the root causes of disease rather than merely managing downstream symptoms.

My areas of clinical leadership within our team include:

• Biomechanical and musculoskeletal assessment: Evaluating posture, gait, range of motion, joint mechanics, and movement faults that contribute to pain and functional limitation
• Chiropractic spinal manipulation and mobilization: Restoring joint mobility, reducing nociceptive input, and modulating the autonomic nervous system
• Soft-tissue therapies: Myofascial release, instrument-assisted soft tissue mobilization (IASTM), and neuromuscular re-education
• Corrective exercise and rehabilitation: Developing progressive movement programs tailored to each patient’s functional capacity and pain level
• Functional medicine assessment and treatment: Comprehensive laboratory evaluation, gut microbiome assessment, hormonal analysis, nutritional interventions, and targeted supplementation protocols
• Behavioral lifestyle medicine: Sleep optimization, stress management, motivational interviewing, and patient education on the biology of obesity

The Multidisciplinary Ecosystem: Who Else Is on Our Team

Our clinical team extends beyond Dr. Cardenas and me to include:

• Registered Dietitian Nutritionists (RDNs) experienced in obesity care, anti-inflammatory dietary protocols, and trauma-informed nutritional counseling
• Registered Nurses (RNs) and health coaches trained in behavioral counseling, motivational interviewing, and chronic disease management.
• Physical therapists and exercise physiologists specializing in graded rehabilitation and joint-friendly progressive exercise
• Behavioral health providers skilled in cognitive-behavioral therapy (CBT), acceptance-based strategies, and trauma-informed care
• Bariatric program partnerships at accredited centers with structured pre- and post-operative support pathways
• Case managers and billing professionals who coordinate insurance navigation, prior authorizations, and patient financial counseling

We operate as both an in-person and telehealth hybrid practice, which dramatically expands access for patients in rural areas, those with mobility limitations, and those with demanding work schedules that would otherwise make frequent follow-up visits impossible.

Obesity as a Chronic Disease: The Foundational Concept That Changes Everything

Defining the Disease: Chronicity, Relapse, and Biological Defense

Before I can explain how we treat obesity, I need to explain what we are actually treating. The most important conceptual shift in modern obesity medicine is recognizing that obesity is not a failure of willpower. It is a chronic, relapsing disease characterized by biological defense mechanisms that actively work against weight loss and sustain weight regain after any period of caloric restriction.

The biology here is compelling and important. When a person loses weight, the body responds with a coordinated set of physiological adaptations designed to restore the lost weight:

• Adaptive thermogenesis: Resting metabolic rate (RMR) drops by more than predicted by the change in body mass alone. The body becomes metabolically more efficient, burning fewer calories at rest than before weight loss (Hall & Kahan, 2018).
• Neurohormonal appetite amplification: Levels of leptin, the satiety hormone secreted by adipose tissue, fall dramatically after weight loss, removing the primary satiety signal to the hypothalamus. At the same time, ghrelin, the hunger hormone secreted by the stomach, rises and remains elevated, creating a persistent biological drive to eat more (MacLean et al., 2015).
• Central nervous system remodeling: The hypothalamic circuits that regulate energy balance adapt to the reduced fat mass by increasing the drive toward energy intake and reducing the drive toward energy expenditure.

These adaptations can persist for years after weight loss and are the primary explanation for why most people who lose weight through lifestyle modification alone regain most or all of it within five years. This is not a character flaw. It is normal human physiology responding to what the body perceives as an energy deficit threat.

Understanding this biology is clinically essential because it reframes the entire treatment paradigm. Episodic interventions (a six-week diet program, a “cleanse,” a boot camp) are fundamentally mismatched to the long-term nature of the disease. What obesity requires is the same thing that diabetes and hypertension require: a permanent, adaptive, medically supervised care relationship.

The Heterogeneity of Obesity: Why One-Size-Fits-All Fails

Obesity is not a single condition. It is a phenotypically heterogeneous disease with multiple underlying biological pathways, environmental drivers, and clinical presentations. The causes and clinical phenotypes vary widely across patients:

• Genetic and epigenetic factors account for a significant proportion of obesity risk. Genome-wide association studies have identified over 900 genetic loci associated with BMI, and polygenic risk scores can now predict substantial variation in obesity susceptibility (Yeo, 2022).
• Environmental exposures, including obesogenic chemicals (endocrine disruptors such as bisphenol A, phthalates, and organochlorine pesticides), food environment, neighborhood safety, and socioeconomic access to health-promoting resources, profoundly shape obesity risk.
• Medications including certain antipsychotics, antidepressants, corticosteroids, beta-blockers, and anticonvulsants cause clinically significant weight gain in many patients, creating iatrogenic obesity that requires a specific clinical approach.
• Neurobehavioral drivers, including food addiction patterns, emotional eating, binge eating disorder, and night eating syndrome, represent distinct biological and behavioral phenotypes that require targeted interventions.
• Sleep disruption from obstructive sleep apnea (OSA), shift work, insomnia, or poor sleep hygiene dysregulates appetite hormones. It impairs glucose metabolism in ways that make weight management much harder.
• Chronic pain reduces physical activity capacity and drives the neurohormonal stress response, creating a biological environment hostile to weight loss.
• Socioeconomic and psychosocial factors, including poverty, food insecurity, chronic stress, adverse childhood experiences (ACEs), and racial and ethnic discrimination, interact with biology in complex bidirectional feedback loops (Hruby & Hu, 2015).

This heterogeneity is why the personalized, integrative approach I practice at Injury Medical Clinic PA produces better outcomes than generic dietary advice or a one-size-fits-all weight loss program. Every patient I see receives an individualized assessment of their specific biological, behavioral, environmental, and psychosocial drivers of obesity.

The Complications of Obesity: Over 200 Ways the Disease Harms Health

One of the most important reasons to treat obesity with urgency and rigor is the sheer breadth and severity of the health complications it drives. Research has documented that excess adiposity is causally linked to over 200 health conditions, spanning virtually every organ system. Here is a detailed overview of the major categories:

Cardiovascular Complications

• Hypertension: Obesity promotes elevated blood pressure through increased cardiac output, activation of the renin-angiotensin-aldosterone system (RAAS) by adipose-derived signals, increased sympathetic nervous system activity, and endothelial dysfunction driven by chronic inflammation and oxidative stress.
• Coronary artery disease: Obesity accelerates atherosclerosis through dyslipidemia, hypertension, insulin resistance, and systemic inflammation, all of which damage the endothelium and promote plaque formation.
• Heart failure, with particularly strong associations between obesity and heart failure with preserved ejection fraction (HFpEF), which is increasingly recognized as an obesity-related phenotype.
• Atrial fibrillation: Structural and electrical remodeling of the atria, driven by hypertension, inflammation, and pericardial fat accumulation.
• Venous thromboembolism (VTE): Including deep vein thrombosis (DVT) and pulmonary embolism (PE).

Metabolic Complications

• Type 2 diabetes mellitus: The convergence of insulin resistance and progressive beta cell failure, driven by adipokine dysregulation, ectopic fat deposition, and chronic inflammation.
• Metabolic syndrome: The dangerous cluster of central obesity, hypertension, elevated fasting glucose, elevated triglycerides, and reduced HDL cholesterol.
• Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH): Driven by ectopic fat deposition in the liver, with the potential to progress to cirrhosis and hepatocellular carcinoma.
• Dyslipidemia: Elevated triglycerides, reduced HDL, and small, dense LDL particles that are particularly atherogenic.
• Polycystic ovary syndrome (PCOS), hyperuricemia, and gout.

Musculoskeletal Complications

• Knee osteoarthritis: Research shows that each pound of body weight adds about four pounds of force across the knee joint during walking, dramatically accelerating cartilage degradation (Messier et al., 2005). Obesity also promotes knee osteoarthritis through metabolic mechanisms, including adipokine-driven cartilage breakdown.
• Low back pain and lumbar spine dysfunction: Excess abdominal adiposity shifts the center of gravity anteriorly, forcing the lumbar spine into hyperlordosis and placing enormous compressive and shear forces on the intervertebral discs and facet joints.
• Hip osteoarthritis, plantar fasciitis, carpal tunnel syndrome, and widespread musculoskeletal pain.

Respiratory Complications

• Obstructive sleep apnea (OSA): Excess adipose tissue in the neck, pharynx, and chest wall increases upper airway collapsibility during sleep.
• Obesity hypoventilation syndrome (OHS): Chronic respiratory compromise leading to hypercapnia.
• Asthma: Airway hyperresponsiveness amplified by inflammatory mechanisms.

Oncological Complications

Obesity is a significant risk factor for at least 13 cancers, including endometrial, postmenopausal breast, colorectal, esophageal, pancreatic, renal cell, hepatocellular, gallbladder, thyroid, and ovarian cancers. The biological mechanisms include chronic inflammation, elevated insulin and IGF-1, estrogen produced by adipose-tissue aromatase, and oxidative stress.

Neurological and Psychiatric Complications

• Depression and anxiety: Driven by inflammatory cytokines crossing the blood-brain barrier and disrupting neurotransmitter function, compounded by the psychosocial burden of weight stigma.
• Cognitive decline and dementia: Midlife obesity is associated with significantly increased risk of Alzheimer’s disease, mediated by vascular injury, insulin resistance, and neuroinflammation.
• Idiopathic intracranial hypertension (IIH).

Reproductive, Endocrine, and Dermatological Complications

• Infertility in both men and women, pregnancy complications, gestational diabetes, and preeclampsia.
• Hypothyroidism, acanthosis nigricans, intertrigo, lymphedema, and striae.

The Physiology of Obesity: Understanding the Biology We Are Treating

The Hypothalamus as the Master Regulator of Energy Balance

The hypothalamus is the brain’s primary control center for appetite and energy homeostasis. It receives a continuous stream of peripheral signals and integrates them into behavioral and physiological responses. The key signaling molecules include:

• Leptin: Secreted by adipose tissue in proportion to fat mass, leptin signals to the arcuate nucleus of the hypothalamus to suppress appetite and increase energy expenditure. In obesity, leptin resistance develops, in which the hypothalamus becomes insensitive to leptin’s satiety signal despite dramatically elevated leptin levels. The brain, in effect, cannot “see” the fat it is carrying, creating a state of perceived energy deficit and sustained appetite drive.
• Ghrelin: Secreted by the stomach mucosa, ghrelin is the primary orexigenic (appetite-stimulating) hormone. Ghrelin levels rise sharply before meals and fall after eating. In some patients with obesity, ghrelin dynamics are dysregulated, contributing to persistent hunger and impaired satiety.
• Insulin: Beyond its role in glucose metabolism, insulin acts within the hypothalamus to suppress appetite. Insulin resistance, central to metabolic obesity, impairs this appetite-suppressing effect, further amplifying the drive to eat.
• GLP-1 (Glucagon-Like Peptide-1) and PYY (Peptide YY): Gut-derived hormones that signal satiety after meals. In many patients with obesity, the secretion of these hormones is reduced, and receptor sensitivity is impaired, contributing to overeating and the failure of normal meal termination signals.

Adipose Tissue as an Endocrine Organ: The Adipokine Dysregulation of Obesity

One of the most profound conceptual advances in obesity medicine over the past 30 years has been the recognition that adipose tissue is not a passive energy storage depot. It is an active endocrine organ that secretes dozens of biologically active molecules, collectively called adipokines, which regulate insulin sensitivity, inflammation, appetite, cardiovascular function, and immune activity.

In lean individuals, the adipokine profile supports metabolic health. In obesity, the expanded and dysfunctional adipose tissue, particularly visceral adipose tissue (VAT) surrounding the abdominal organs, produces a dramatically different and harmful profile:

• Elevated pro-inflammatory adipokines: Including TNF-alpha (tumor necrosis factor alpha), IL-6 (interleukin-6), resistin, and excess leptin, these molecules promote insulin resistance, endothelial dysfunction, atherosclerosis, and systemic inflammation.
• Reduced anti-inflammatory adipokines: Most notably adiponectin, which normally improves insulin sensitivity, reduces inflammation, and provides cardiovascular protection. Adiponectin levels fall markedly as adipose tissue expands, removing a critical metabolic protection.
• Macrophage infiltration: As adipocytes expand beyond their functional capacity, they undergo apoptosis and attract macrophages that form characteristic “crown-like structures” around dead adipocytes. These macrophages produce high levels of TNF-alpha and IL-1beta, amplifying local and systemic inflammation.

This adipokine-driven inflammation is central to the insulin resistance that characterizes metabolic obesity and underlies type 2 diabetes, NAFLD, cardiovascular disease, and the progression of many obesity-related cancers.

The Autonomic Nervous System and Metabolic Regulation

The autonomic nervous system (ANS) regulates a wide range of metabolic functions, including insulin secretion and sensitivity, appetite regulation via vagal nerve signaling, cardiovascular function, adrenal hormone output (including cortisol and epinephrine), and digestive function and gut motility.

Patients with obesity consistently show a pattern of reduced parasympathetic tone (the “rest and digest” branch of the ANS) and elevated sympathetic tone (the “fight or flight” branch). This autonomic imbalance:

• Increases insulin resistance by promoting hepatic glucose production and impairing glucose uptake in peripheral tissues
• Elevates blood pressure through vasoconstriction and increased heart rate
• Dysregulates appetite by altering vagal afferent signaling from the gut to the brain
• Impairs digestion and gut motility, contributing to the gut dysbiosis increasingly recognized as a contributor to metabolic dysfunction
• Promotes chronic low-grade inflammation through sympathetic activation of immune cells

Heart rate variability (HRV), a measure of the beat-to-beat variation in heart rate that reflects the balance between sympathetic and parasympathetic nervous system activity, is consistently reduced in patients with obesity and improves with interventions that restore autonomic balance. This is one physiological reason chiropractic care, which clinical studies show can influence HRV (Roy et al., 2009), may help improve metabolic function in patients with obesity.

The Gut Microbiome and Its Role in Obesity

Research over the past decade has dramatically expanded our understanding of the gut microbiome, the approximately 38 trillion microorganisms inhabiting the human gastrointestinal tract, as a major determinant of metabolic health and obesity risk. Key findings include:

• Patients with obesity consistently show reduced microbial diversity compared to lean individuals, with shifts in the ratio of Firmicutes to Bacteroidetes, the two dominant bacterial phyla in the gut.
• Certain microbial communities are associated with increased energy harvest from food, meaning they extract more calories from the same dietary intake through enhanced fermentation of dietary fiber into short-chain fatty acids (SCFAs).
• Gut microbiome dysbiosis increases intestinal permeability, allowing lipopolysaccharide (LPS), a component of Gram-negative bacterial cell walls, to enter the systemic circulation. This creates metabolic endotoxemia, which drives chronic low-grade inflammation, insulin resistance, and hepatic lipid accumulation.
• Early-life factors, including mode of delivery, breastfeeding versus formula feeding, and early antibiotic use, significantly influence gut microbiome composition and long-term metabolic risk.

In my functional medicine practice, assessing and restoring the gut microbiome is central to obesity treatment, addressed through dietary interventions emphasizing prebiotic fiber and fermented foods, targeted probiotic supplementation, elimination of pro-inflammatory dietary inputs, and, when indicated, gut-targeted antimicrobial therapy for identified dysbiosis.

The HPA Axis, Cortisol, and Visceral Fat Accumulation

The relationship between chronic stress, cortisol, and visceral adiposity is one of the most clinically important biological connections in obesity medicine, and it is directly relevant to the harm caused by weight stigma. The hypothalamic-pituitary-adrenal (HPA) axis responds to physical, psychological, and environmental stressors by triggering cortisol secretion from the adrenal cortex.

Chronically elevated cortisol:

• Directly promotes visceral fat deposition by upregulating glucocorticoid receptor activity in abdominal adipocytes
• Drives insulin resistance by opposing insulin signaling in muscle and liver
• Increases appetite and food-seeking behavior, particularly for high-calorie, high-fat, and high-sugar foods that activate the mesolimbic dopamine reward system
• Impairs sleep architecture by disrupting the normal nocturnal cortisol rhythm, which in turn dysregulates leptin and ghrelin and further amplifies appetite
• Suppresses the prefrontal cortex, impairing executive function and the capacity for deliberate, health-promoting decision-making

This is not merely an academic observation. It has direct clinical implications: weight stigma in healthcare settings activates the HPA axis, elevates cortisol, and produces the exact physiological cascade that worsens obesity (Tomiyama et al., 2014). When we fail to address stigma in our clinical environments, we are actively contributing to the pathophysiology of the disease we are trying to treat.

Stigma-Free Care: Why the Clinical Environment Must Reflect Patient Dignity

The Physiological Cost of Weight Stigma

I want to spend significant time on this topic because I believe it is the most consistently underaddressed element of obesity care in clinical medicine. Weight stigma, the negative attitudes, stereotypes, and discriminatory behaviors directed toward people because of their body weight, is not merely a social justice issue. It is a clinical intervention variable with measurable physiological consequences.

Research has demonstrated that exposure to weight-based stigma activates the HPA axis, triggering cortisol release that directly worsens insulin resistance, promotes visceral fat accumulation, disrupts sleep, amplifies appetite, and suppresses the prefrontal cortical function needed for behavior change (Tomiyama et al., 2014). When a patient with obesity experiences stigma in a healthcare setting, the physiological response to that stigma can directly worsen the very condition the clinic is attempting to treat. This creates a vicious cycle: stigma increases stress, stress increases cortisol, elevated cortisol promotes fat storage and appetite dysregulation, obesity worsens, and further stigma follows.

Beyond the acute physiological response, weight stigma in healthcare settings causes patients to avoid or delay seeking care, disengage from treatment, internalize shame that undermines self-efficacy, and experience worse mental health and quality of life (Phelan et al., 2015). In my own clinical observations at HealthCoachclinic, patients who have received respectful, dignity-affirming care after years of stigmatizing experiences in other settings consistently report higher engagement, greater adherence to treatment plans, and measurably better outcomes.

Building a Stigma-Free Clinical Environment: Every Detail Matters

The clinical environment communicates its values before a single word is exchanged. Every element of the physical space, the written materials, the website, the marketing imagery, and the communication style of every staff member either reinforces or undermines patient dignity. Here is what we prioritize at Injury Medical Clinic PA:

Physical Environment and Equipment

• Seating: All waiting room and examination room chairs accommodate diverse body sizes, with some armless and some with sturdy arms to assist patients with hip or knee pain when rising. All seating is rated for appropriate weight capacity, has firm cushions for stability, and is spaced to accommodate mobility aids.
• Scales: High-capacity scales with low step heights are located in private alcoves, with the display angled away from public view. We always ask patients whether they wish to see or hear their weight. We never comment on the number.
• Blood pressure cuffs: We have large and thigh cuffs readily available and use the correct size without drawing attention to it.
• Examination tables: Wide, stable, high-capacity tables with easy height adjustment and step stools with handles.
• Gowns and drapes: Extra-large sizes available, with full-coverage options.
• Restrooms: Floor-mounted toilets with split seats, grab bars, and adequate space for patients of all sizes.
• We prepare all equipment before the patient enters the room, so no adjustments are needed in the patient’s presence.

Imagery and Marketing Materials

The images we choose for our website, our waiting room walls, and our educational materials communicate our values about people with obesity. Many healthcare settings, even those focused on health promotion, use images that inadvertently perpetuate stigma:

• Photographs taken from behind or with heads cropped out, as though the patient’s identity is a source of shame
• Images of people with obesity eating unhealthy foods, reinforcing harmful stereotypes
• Marketing materials that promote thinness as the aspirational ideal or feature glamour imagery disconnected from the health-focused mission of the clinic

We do not use any of these. Instead, our materials feature images from Stigma-Free. These curated galleries portray people with obesity living their lives, exercising, cooking, laughing with family, working, and navigating the world as full, multidimensional human beings. Free resources for stigma-free medical imagery include:

• Rudd Center Image Gallery (University of Connecticut Rudd Center for Food Policy and Health)
• OAC Image Gallery (Obesity Action Coalition)
• Obesity Canada Image Gallery
• Obesity Medicine Association Image Gallery

Using these galleries is one of the simplest, most immediate steps any practice can take to create a stigma-free clinical environment.

Language in All Clinical Communications

Language is a clinical tool. The words we choose in spoken communication, written materials, and clinical documentation signal whether we view obesity as a disease or a failing. Our standards include:

• Person-first language: “Person with obesity,” “patient with obesity,” “person living with obesity” rather than “obese person.” This parallels the language standards already established for other chronic diseases: we say “person with diabetes,” not “diabetic person.”
• Avoidance of stigmatizing terminology: We do not use the term “morbidly obese,” which has no clinical meaning that is not better captured by “class III obesity” and which carries profound stigmatizing weight. We do not use phrases like “failed to lose weight,” “non-compliant,” or “overweight due to poor choices.”
• Documentation is patient-readable: Patients now routinely read their clinical notes through patient portal access. Every word we write in a chart is a word a patient may read. Respectful, accurate, person-first language throughout documentation is both clinically and ethically essential.
• Obesity as a disease, not a behavior: Our language consistently frames obesity as a chronic, biologically driven disease with genetic, environmental, metabolic, and behavioral determinants, never as a simple consequence of poor decisions.

Staff Training: Scripts and Behaviors That Build Trust

Every person who interacts with a patient at our clinic, from the front desk staff who greet patients to the billing team who handles financial conversations, is trained in weight-neutral, person-centered communication. Specific training elements include:

• Greeting patients warmly: “Welcome, we are glad you are here” with genuine eye contact and a calm tone.
• Weight measurement language: “Would you like to see your weight today? We can record it without displaying it if you prefer.”
• Equipment language: “I will use the cuff that best fits your arm” rather than any phrasing that draws attention to size.
• Privacy: “Let’s step into a private area to go over your results.”
• Explicit prohibition: We explicitly ban stigmatizing jokes or remarks even in staff-only settings. The culture of dignity we project publicly must be genuine and consistent internally.
• Quarterly refresher training on people-first language, implicit bias, and motivational communication.
• Anonymous patient feedback mechanisms focused specifically on dignity and comfort, with rapid corrective action when lapses are identified.

Balancing Body and Metabolism- Video

The Four Pillars of Obesity Treatment: Physiology, Evidence, and Clinical Application

Pillar One: Nutrition Therapy

Nutritional intervention is the foundational pillar of obesity treatment, but it is essential to understand that there is no single optimal dietary pattern for all patients with obesity. Modern nutritional science has established with considerable confidence that different patients respond differently to different dietary approaches, based on their genetics, gut microbiome composition, metabolic phenotype, food preferences, cultural background, and lifestyle context. This personalized approach is central to the functional medicine framework I apply in my practice.

The Anti-Inflammatory Dietary Foundation

Regardless of the specific dietary pattern chosen, an anti-inflammatory dietary foundation is essential for patients with obesity. The physiological rationale is compelling: obesity is a state of chronic systemic inflammation driven by adipokine dysregulation, gut dysbiosis, and inflammatory signals from visceral fat. A diet that amplifies this inflammation through ultra-processed foods, refined sugars, industrial seed oils (omega-6 dominant), and food additives directly worsens insulin resistance, adipokine dysregulation, and obesity-related metabolic complications. Conversely, a diet rich in omega-3 fatty acids, polyphenols, prebiotic fiber, and whole, minimally processed foods actively reduces the inflammatory burden, supports the gut microbiome, improves insulin sensitivity, and facilitates weight loss.

The Mediterranean Dietary Pattern

The Mediterranean dietary pattern holds the strongest and most consistent evidence base of any dietary approach for the conditions commonly associated with obesity. The landmark PREDIMED trial showed that a Mediterranean diet supplemented with extra-virgin olive oil or nuts reduced the risk of major cardiovascular events by about 30% compared with a control low-fat diet in high-risk patients, many of whom had obesity (Estruch et al., 2013). The Mediterranean pattern emphasizes:

• High consumption of extra-virgin olive oil as the primary fat source, providing monounsaturated fats and potent anti-inflammatory polyphenols
• Abundant vegetables, legumes, fruits, whole grains, and nuts, providing prebiotic fiber, phytonutrients, and micronutrients
• Regular consumption of fatty fish and seafood, providing long-chain omega-3 fatty acids (EPA and DHA)
• Moderate consumption of poultry, eggs, and dairy
• Limited red and processed meats and refined sugars

Higher-Protein Approaches for Lean Mass Preservation

During caloric restriction for weight loss, lean muscle loss is a significant risk, reducing resting metabolic rate and accelerating adaptive thermogenesis that drives weight regain. Higher-protein dietary approaches targeting 1.2 to 1.6 grams of protein per kilogram of ideal body weight protect lean mass during weight loss, enhance satiety through hormonal and mechanical mechanisms, and support the resistance training programs central to our physical activity pillar (Leidy et al., 2015). In my practice, I consistently emphasize protein adequacy as one of the most clinically impactful and practically accessible nutritional interventions for patients with obesity.

Low-Glycemic and Low-Carbohydrate Approaches

For patients with significant insulin resistance or type 2 diabetes, a low-glycemic or low-carbohydrate approach can be particularly effective in reducing postprandial glucose and insulin spikes, improving insulin sensitivity, promoting weight loss, reducing triglycerides, and decreasing diabetes medication requirements. The ketogenic diet (very low carbohydrate, high fat) has shown impressive short-term results in some patients. Still, its long-term sustainability and safety require individualized evaluation, particularly in patients with kidney disease, a history of eating disorders, or certain lipid abnormalities (Gardner et al., 2018).

Time-Restricted Eating and Intermittent Fasting

Time-restricted eating (TRE) and intermittent fasting approaches offer physiological benefits through metabolic switching (the shift from glucose to fat as the primary fuel source during fasting periods), potential autophagy induction, and improved circadian rhythm alignment. A pivotal study by Sutton et al. (2018) demonstrated that early time-restricted feeding improved insulin sensitivity, blood pressure, and oxidative stress even without caloric restriction. In my practice, I integrate TRE cautiously, particularly for patients on medications such as insulin or sulfonylureas that carry hypoglycemia risk during fasting periods, always coordinating medication adjustments with Dr. Cardenas.

Pain-Sensitive Nutritional Planning

One element of nutritional counseling that is unique to an integrative chiropractic and pain management practice is pain-sensitive dietary planning. Patients with significant musculoskeletal pain often struggle with the physical demands of meal preparation, cooking, and grocery shopping. I routinely provide guidance on:

• Batch preparation methods that minimize repetitive joint stress during cooking
• Ergonomic kitchen setups that reduce lumbar and upper extremity loading
• Anti-inflammatory dietary timing around chiropractic treatment sessions to optimize recovery
• Omega-3 supplementation (at doses of 2 to 4 grams of EPA+DHA daily) as an evidence-supported adjunct to dietary omega-3 sources, with meaningful anti-inflammatory and joint-protective effects

Pillar Two: Physical Activity and Functional Movement

Physical activity is the most powerful tool available for maintaining weight loss, improving insulin sensitivity, protecting cardiovascular health, and supporting mental wellbeing in patients with obesity. The physiological mechanisms are numerous and deeply important:

Insulin Sensitivity and Glucose Disposal

Exercise stimulates GLUT4 transporter translocation to the muscle cell surface through an insulin-independent pathway, allowing glucose uptake to occur without requiring insulin signaling. This is why exercise produces immediate glycemic improvement even in patients with severe insulin resistance, making it a critical component of metabolic obesity management (Richter & Hargreaves, 2013). Both aerobic and resistance exercise improve insulin sensitivity through complementary but distinct mechanisms: aerobic exercise primarily enhances oxidative capacity. It reduces visceral adipose tissue, while resistance training builds lean muscle mass, which serves as a metabolically active glucose disposal sink.

Myokines and the Anti-Inflammatory Effect of Exercise

Skeletal muscle is an endocrine organ that secretes myokines during contraction with systemic anti-inflammatory effects. The most studied myokine, IL-6 (which, notably, has anti-inflammatory effects when secreted by muscle as opposed to pro-inflammatory effects when secreted by adipose tissue), stimulates fat oxidation and inhibits the pro-inflammatory cytokines TNF-alpha and IL-1beta. Other myokines including irisin, myonectin, and musclin further support metabolic health through effects on adipose tissue browning, hepatic function, and insulin signaling (Petersen & Pedersen, 2005).

Resting Metabolic Rate and Lean Mass Protection

Perhaps the most clinically significant long-term benefit of progressive resistance training in obesity management is preserving lean muscle mass during caloric restriction. As discussed in the nutrition section, weight loss through caloric restriction without resistance training causes significant muscle loss, which reduces resting metabolic rate and increases the likelihood of weight regain. A structured resistance training program, performed two to three times per week at intensities appropriate to the patient’s musculoskeletal health, is not optional in a comprehensive obesity management plan. It is essential.

Program Design Principles

In designing physical activity programs for patients with obesity, I follow several evidence-based principles:

• Start where the patient is: Initial exercise prescriptions are based on the patient’s current functional capacity, pain level, and movement confidence. Beginning with a five-minute walk is clinically appropriate and far more likely to build long-term adherence than a program that immediately demands 30 minutes.
• Break activity into manageable bouts: Walking for three ten-minute periods daily is metabolically equivalent to walking for one thirty-minute period and is more achievable for patients with significant pain or deconditioning.
• Low-impact modalities first: Walking, aquatic exercise, recumbent cycling, and seated resistance training are ideal entry points for patients with knee, hip, or spine pain.
• Progressive overload: Gradually increasing duration, frequency, and intensity over weeks and months, guided by the patient’s tolerance and functional progress.
• Resistance training integration: Progressing to two to three structured resistance training sessions per week as musculoskeletal health allows.

Pillar Three: Behavioral Counseling

The behavioral dimension of obesity is not separable from its biology. The brain’s response to food, stress, sleep deprivation, and emotional distress is fundamentally neurobiological, and understanding the neuroscience of eating behavior is essential for designing effective behavioral interventions.

The Dopaminergic Reward System and Food

The brain’s mesolimbic dopaminergic system, the reward circuit, plays a central role in the motivation to eat and the rewarding experience of food consumption. Modern ultra-processed foods are engineered with specific combinations of fat, sugar, salt, and flavor compounds that activate dopamine release at levels that can approach those seen with addictive substances. Over time, repeated exposure to hyperpalatable foods produces dopamine receptor downregulation in the striatum, meaning that higher and higher food intake is required to produce the same level of reward. This neuroadaptation is analogous to the tolerance phenomenon in substance use disorders and is the biological substrate of food addiction patterns in many patients with obesity (Gearhardt et al., 2016).

Research has also shown that patients with obesity often have reduced baseline dopamine receptor availability in the reward circuitry, creating a biological predisposition toward food reward-seeking behavior that cannot be corrected through willpower alone. Effective behavioral counseling acknowledges this neurobiological reality and designs interventions accordingly, including:

• Dietary restructuring to reduce the reward density of the food environment while increasing nutrient density
• Gut microbiome restoration to improve the gut-brain axis signaling that modulates food reward.
• Nutrient support for dopamine synthesis, including tyrosine, vitamin B6, zinc, and iron
• Collaborative referral to behavioral health for patients with binge eating disorder, emotional eating, or food addiction patterns

Motivational Interviewing and Behavior Change

Motivational interviewing (MI) is an evidence-based clinical communication approach specifically designed to help patients explore and resolve ambivalence about behavior change. It is built on four core principles: expressing empathy, developing discrepancy between current behavior and stated values, rolling with resistance rather than confronting it, and supporting self-efficacy. In obesity care, MI is particularly valuable because many patients have a long history of failed treatment attempts and have developed defensive responses to unsolicited advice about weight and lifestyle. MI creates a collaborative, non-coercive therapeutic space where the patient’s motivations and values drive the conversation.

Cognitive-Behavioral Strategies

Cognitive-behavioral therapy (CBT) for obesity targets the thoughts, beliefs, and behavioral patterns that perpetuate overeating, physical inactivity, and emotional eating. Core CBT strategies include:

• Identifying cognitive distortions: All-or-nothing thinking (“I already ate something unhealthy, so the whole day is ruined”), catastrophizing, and emotional reasoning are common cognitive patterns that derail weight management efforts.
• Behavioral contracts and structured planning: Creating specific, measurable, achievable, relevant, and time-bound (SMART) goals for dietary and activity behavior.
• Environmental restructuring: Modifying the food environment (removing hyperpalatable foods from the home, making healthy foods visible and accessible) to reduce the cognitive load of healthy eating.
• Relapse prevention planning: Anticipating high-risk situations and developing specific coping scripts in advance.

Sleep Optimization as a Metabolic Intervention

Sleep is perhaps the most underappreciated metabolic intervention in obesity care. The physiological consequences of inadequate or disrupted sleep on weight regulation are profound:

• After a single night of sleep restriction, ghrelin increases, and leptin decreases, creating a powerful, biologically driven increase in appetite.
• Sleep restriction impairs prefrontal cortical function, reducing the inhibitory control needed to resist impulsive eating.
• Disrupted sleep dysregulates the HPA axis, elevating cortisol and promoting visceral fat deposition.
• Inadequate sleep impairs glucose metabolism and insulin sensitivity in ways that are partially independent of dietary intake.

Prioritizing sleep hygiene, evaluating and treating obstructive sleep apnea, and supporting circadian rhythm alignment through consistent sleep and wake times, light exposure, and meal timing are all integral components of the behavioral pillar in our obesity management program.

Stress Management and the HPA Axis

Chronic psychosocial stress is both a cause and a consequence of obesity. As described in the physiology section, elevated cortisol from chronic HPA axis activation directly promotes visceral fat accumulation, insulin resistance, and appetite dysregulation. Our behavioral counseling incorporates:

• Paced breathing and diaphragmatic breathing exercises, which activate the parasympathetic nervous system and reduce sympathetic tone
• Mindfulness-based stress reduction (MBSR) principles applied to eating behavior and stress management
• Social support activation: Identifying and strengthening the patient’s social support network, which is one of the strongest predictors of long-term weight maintenance
• Addressing adverse childhood experiences (ACEs) and trauma history with trauma-informed care approaches, recognizing that ACEs are strongly associated with obesity through HPA axis dysregulation and emotional eating

Pillar Four: Medical Management Including Pharmacotherapy and Surgical Pathways

The Biological Rationale for Pharmacotherapy

Even with optimal adherence to nutritional, physical activity, and behavioral interventions, many patients with obesity will experience biologically driven weight regain due to the adaptive neurohormonal responses described earlier. Anti-obesity medications (AOMs) target specific biological mechanisms that drive excess caloric intake or impair caloric expenditure, providing pharmacological support for the body’s weight-regulation systems. The clinical rationale for pharmacotherapy is the same as for managing any other chronic disease with a strong biological driver. When disease biology works against the patient’s best efforts, medication provides a necessary physiological counterweight (Apovian et al., 2015).

GLP-1 Receptor Agonists: The Most Significant Advance in Obesity Pharmacotherapy

GLP-1 (Glucagon-Like Peptide-1) is a hormone secreted by L-cells in the small intestine and colon in response to food intake. It stimulates glucose-dependent insulin secretion, inhibits glucagon secretion, slows gastric emptying, acts on hypothalamic appetite centers to reduce appetite and promote satiety, and exerts direct cardiovascular protective effects. In obesity, GLP-1 secretion is often reduced, and receptor sensitivity is impaired.

GLP-1 receptor agonists (GLP-1 RAs) are synthetic molecules that mimic and amplify the actions of native GLP-1, producing dramatic clinical effects:

• The STEP 1 trial showed that weekly subcutaneous semaglutide 2.4 mg (Wegovy) produced an average weight loss of 9% of initial body weight over 68 weeks, compared with 2.4% in the placebo group (Wilding et al., 2021).
• The SELECT trial demonstrated that semaglutide significantly reduced the risk of major adverse cardiovascular events in patients with obesity and established cardiovascular disease but without diabetes (Lincoff et al., 2023).
• The SURMOUNT-1 trial of tirzepatide (Zepbound), a dual GLP-1/GIP receptor agonist, demonstrated average weight loss of 9% at the 15 mg dose over 72 weeks, approaching outcomes previously seen only with bariatric surgery (Jastreboff et al., 2022).

Currently available anti-obesity pharmacological agents in the United States include:

• Semaglutide (Wegovy): Weekly subcutaneous injection, FDA-approved for obesity
• Liraglutide (Saxenda): Daily subcutaneous injection, FDA-approved for obesity
• Tirzepatide (Zepbound): Weekly subcutaneous injection, dual GLP-1/GIP agonist, FDA-approved for obesity
• Phentermine-topiramate (Qsymia): Combination oral medication; effective but contraindicated in pregnancy and cardiovascular disease
• Bupropion-naltrexone (Contrave): Targets the brain’s reward pathways to reduce food cravings
• Orlistat (Xenical, Alli): Gastrointestinal lipase inhibitor; modest weight loss with significant gastrointestinal side effects

In my functional medicine practice, I work to enhance the effectiveness of GLP-1 receptor agonists through complementary interventions: the Mediterranean dietary pattern supports a gut microbial environment conducive to endogenous GLP-1 production, gut microbiome restoration may improve receptor sensitivity, inflammation reduction through dietary and supplementation strategies may amplify pharmacological effects, and chiropractic care and rehabilitation enable the physical activity that multiplies the metabolic benefits of these medications.

Bariatric and Endoscopic Procedures

For patients with class III obesity (BMI 40+) or class II obesity (BMI 35-39.9) with significant metabolic complications who have not achieved adequate response to lifestyle and pharmacological interventions, bariatric surgery offers the most effective and durable weight loss available. Procedures including Roux-en-Y gastric bypass, sleeve gastrectomy, and biliopancreatic diversion with duodenal switch produce average weight loss of 25 to 35% of initial body weight and dramatic improvements in type 2 diabetes, hypertension, dyslipidemia, and OSA.

Our clinical role in the bariatric pathway includes identifying appropriate surgical candidates, facilitating referral to accredited bariatric programs, providing pre-operative optimization through nutritional and lifestyle interventions, and delivering post-operative follow-up care including nutritional support, rehabilitation, and management of comorbidities.

Integrative Chiropractic Care in Obesity Management: The Clinical Case for a Vital Intervention

Why Chiropractic Care Belongs at the Center of Obesity Treatment

The role of chiropractic care in obesity management is frequently underestimated, even within integrative medical communities. This underestimation reflects a narrow view of chiropractic as purely a treatment for back pain, rather than a systems-level intervention that addresses the mechanical, neurological, and autonomic dimensions of chronic disease.

In my clinical experience, the patients with obesity who struggle most with physical activity, the cornerstone of long-term weight management, are those with uncontrolled musculoskeletal pain. Knee osteoarthritis, low back pain, plantar fasciitis, hip pain, and cervical dysfunction do not merely make exercise uncomfortable. They make it physiologically irrational for the body: movement that produces pain triggers a protective neuromuscular response that reduces activity capacity, raises sympathetic tone, elevates cortisol, and reduces the patient’s confidence and motivation to continue. By reducing pain and restoring functional movement, chiropractic care directly removes the primary biological barrier to the physical activity that drives metabolic improvement.

Chiropractic Spinal Manipulation: Mechanisms of Action in the Metabolic Context

Chiropractic spinal manipulative therapy (SMT) works through several complementary mechanisms that are directly relevant to obesity treatment:

Nociceptive Input Reduction

The primary and most direct mechanism of SMT involves restoring joint mobility and reducing nociceptive input to the central nervous system. When a spinal segment or peripheral joint is hypomobile, restricted, or biomechanically dysfunctional, it generates elevated levels of nociceptive afferent signals to the dorsal horn of the spinal cord and, through ascending pathways, to the brain. This persistent nociceptive input:

• Sensitizes pain processing pathways, lowering the pain threshold for subsequent stimuli (central sensitization)
• Activates the sympathetic nervous system, elevating cortisol and catecholamines
• Reduces physical activity through pain avoidance behavior

SMT restores normal joint motion, reduces periarticular inflammation, normalizes the mechanoreceptor-to-nociceptor signal ratio in joint afferent nerves, and modulates dorsal horn pain processing through central inhibitory mechanisms. The result is reduced pain, improved mobility, and a physiological environment more conducive to physical activity and metabolic improvement. Systematic reviews have demonstrated that spinal manipulation is an effective treatment for chronic low back pain, which is among the most common musculoskeletal presentations in patients with obesity (Rubinstein et al., 2019).

Autonomic Nervous System Modulation

Beyond its effects on musculoskeletal pain, SMT has been shown to influence the autonomic nervous system in ways that are clinically relevant to metabolic health. Research by Roy et al. (2009) showed that chiropractic adjustments can improve heart rate variability (HRV), a validated marker of parasympathetic tone and autonomic balance. Increased parasympathetic activity:

• Improves insulin sensitivity by enhancing the liver’s glycogen synthesis and reducing hepatic glucose output
• Reduces cortisol secretion by downregulating HPA axis activity
• Improves gut motility and digestive function, supporting gut microbiome health
• Reduces blood pressure through vasodilation and reduced sympathetic vasoconstriction
• Improves sleep quality by supporting the circadian parasympathetic activation needed for restorative sleep

Combined with paced breathing exercises, ribcage mobility work, and vagal nerve activation techniques, chiropractic care becomes a direct physiological intervention for the autonomic dysregulation central to metabolic obesity.

Proprioceptive Enhancement and Neuromuscular Re-Education

Obesity alters sensorimotor function in multiple ways: excess mass shifts the center of gravity and creates abnormal joint loading patterns; chronic pain reduces the quality of proprioceptive input from affected joints; and the sedentary lifestyle associated with obesity further reduces the proprioceptive training stimulus that maintains neuromuscular coordination. SMT and the accompanying corrective exercise and neuromuscular re-education program we implement address these deficits by:

• Restoring normal joint mechanoreceptor function through the stimulation of articular afferents during manipulation
• Improving motor control patterns that reduce energy cost and injury risk during movement
• Rebuilding movement confidence in patients who have become fearful of movement due to pain, reducing fear-avoidance behaviors that limit activity

Soft-Tissue Therapies and Myofascial Release

In addition to spinal manipulation, our chiropractic care integrates myofascial release, instrument-assisted soft tissue mobilization (IASTM), therapeutic massage, and active release techniques to address the fascial restrictions, muscle hypertonicity, and trigger points that accumulate with chronic pain and altered movement patterns in patients with obesity. These interventions:

• Reduce fascial adhesions that restrict movement and contribute to chronic pain.
• Restore muscle length-tension relationships in chronically shortened muscles such as the hip flexors, thoracolumbar erectors, and gastrocnemius-soleus complex.
• Improve blood and lymphatic circulation in affected tissues
• Reduce peripheral nociceptive input from trigger points and myofascial pain generators

Functional Rehabilitation and Exercise Prescription

Chiropractic care at our clinic extends well beyond the treatment table. As an ATN and CCST, I design individualized functional rehabilitation programs that address the specific movement faults, muscle imbalances, and kinetic chain dysfunctions that are common in patients with obesity:

• Core stabilization: Patients with obesity commonly have weak deep core muscles (transversus abdominis, multifidus, pelvic floor) and over-recruited global movers, creating a pattern of lumbar instability and pain. Progressive core stabilization exercises address this directly.
• Hip hinge and glute activation: Weakness and inhibition of the gluteal muscles are extremely common in patients with obesity and chronic low back pain, leading to compensatory lumbar loading during lifting and gait. Hip hinge and glute activation exercises restore proper load distribution.
• Knee and ankle mobility: Restrictions in ankle dorsiflexion and knee joint mobility alter gait mechanics and increase impact forces transmitted to the spine.
• Aquatic therapy: For patients with severe joint pain, aquatic exercise provides a supportive, low-impact environment in which water buoyancy reduces joint loading by up to 80%, allowing movement that would be impossible on land.

Ergonomic Coaching and Graded Activity Exposure

For many patients with obesity who have been inactive for years due to pain, simply returning to movement can trigger fear-avoidance responses, the neuropsychological pattern in which pain leads to fear of movement, which leads to further avoidance, which leads to deconditioning and increased pain. In my practice, I address this through:

• Graded exposure therapy principles applied to physical activity, beginning at levels well below the pain threshold and advancing incrementally
• Ergonomic coaching for daily activities such as sitting, standing, carrying, and sleeping to reduce the cumulative mechanical stress that contributes to chronic pain
• Activity-specific movement training that prepares patients for the specific activities they want to return to, whether that is walking in a park, playing with grandchildren, or returning to an active job

The Functional Medicine Approach to Obesity: Addressing Root Causes Through Systems Biology

Beyond Calories In, Calories Out: The Systems Biology Framework

I want to address directly one of the most persistent and harmful myths in obesity medicine: the “calories in, calories out” model as a complete explanation for obesity. While energy balance is unquestionably a factor in weight regulation, modern systems biology research has established beyond reasonable doubt that obesity is a consequence of complex, multilevel biological dysregulation that involves genetic and epigenetic factors, neuroendocrine dysregulation, gut microbiome composition and function, chronic systemic inflammation, environmental factors, and psychological and behavioral patterns, all interacting in bidirectional feedback loops.

Prescribing a 1,500-calorie diet to a patient with severe insulin resistance, gut dysbiosis, hypothyroidism, vitamin D deficiency, and chronic HPA axis dysregulation without addressing any of these underlying biological drivers is the metabolic equivalent of prescribing reading glasses to a patient with glaucoma. It addresses one narrow aspect of the problem while leaving the underlying disease progression entirely untouched.

The Functional Medicine Matrix Applied to Obesity

The Functional Medicine Matrix provides a comprehensive framework for organizing the biological, psychological, and social factors that contribute to a patient’s health. Applied to obesity, it evaluates:

Assimilation: Digestion, Absorption, and the Gut Microbiome

• Is the patient’s gut microbiome contributing to increased energy harvest from food and driving systemic inflammation through metabolic endotoxemia?
• Are there signs of intestinal dysbiosis or leaky gut (increased intestinal permeability)?
• Does the patient have food sensitivities driving inflammatory responses that worsen insulin resistance?
• Is nutrient absorption adequate, or are nutrient deficiencies impairing metabolic function?

Defense and Repair: Immune Function and Inflammation

• What is the patient’s systemic inflammatory burden, as assessed by high-sensitivity CRP, homocysteine, ferritin, and fibrinogen?
• Are there autoimmune conditions or chronic infections amplifying the inflammatory load?

Energy: Mitochondrial Function and Cellular Energy Production

• Is there evidence of mitochondrial dysfunction, manifesting as fatigue, poor exercise tolerance, or metabolic inflexibility?
• Are nutrient deficiencies, particularly B vitamins, coenzyme Q10, magnesium, and zinc, impairing mitochondrial function?
• Does the patient have adequate thyroid hormone activity to support normal metabolic rate? Importantly, do Free T3 levels reflect adequate active thyroid hormone, or does the patient have impaired T4-to-T3 conversion despite a normal TSH?

Biotransformation and Elimination: Detoxification and Toxic Burden

• Is the patient exposed to obesogenic environmental chemicals (obesogens), including bisphenol A (BPA), phthalates, organochlorine pesticides, and persistent organic pollutants (POPs) that disrupt endocrine function and promote adipogenesis?
• Is the patient’s detoxification capacity, mediated by hepatic Phase I and Phase II enzymes, adequate to manage their toxic burden?

Communication: Hormonal and Neurotransmitter Signaling

• What is the patient’s full hormonal profile, including thyroid hormones, sex hormones (testosterone, estradiol, progesterone, SHBG), adrenal hormones (cortisol, DHEA-S), and metabolic hormones (fasting insulin, leptin, ghrelin)?
• Are hormonal imbalances driving weight gain or impeding weight loss? Conditions such as hypothyroidism, hypogonadism, adrenal fatigue, and sex hormone imbalances are common in patients with obesity and often go undiagnosed.

Structural Integrity: Musculoskeletal and Connective Tissue Health

• What musculoskeletal barriers to physical activity exist, and how can they be addressed through chiropractic care and rehabilitation?
• Is there chronic pain limiting the patient’s ability to engage in the exercise that is essential for metabolic improvement?

Comprehensive Functional Medicine Laboratory Evaluation

In my practice, I routinely order an extensive laboratory panel for patients with obesity that goes far beyond the standard metabolic panel:

Metabolic and Glycemic Assessment

• Fasting glucose and insulin
• HOMA-IR (Homeostatic Model Assessment of Insulin Resistance): A calculated index of insulin resistance derived from fasting glucose and insulin, far more sensitive than fasting glucose alone
• HbA1c
• Full fasting lipid panel with advanced lipoprotein testing (LDL particle number and size, HDL particle number)
• Triglycerides and triglyceride-to-HDL ratio (a highly sensitive marker of insulin resistance)

Thyroid Function (Comprehensive)

• TSH
• Free T4 (thyroxine)
• Free T3 (triiodothyronine): The metabolically active form; often reduced even when TSH and T4 are normal
• Reverse T3: An inactive metabolite of T4 that can accumulate under chronic stress and inflammation, blocking T3 receptors and producing a functional hypothyroid state.
• TPO antibodies and thyroglobulin antibodies: To identify Hashimoto’s thyroiditis, which is both associated with and exacerbated by obesity

Adrenal Function

• Morning serum cortisol
• DHEA-S (a marker of adrenal reserve that tends to fall with chronic stress and aging)
• 24-hour urinary cortisol when adrenal dysfunction is suspected

Sex Hormone Assessment

• Total and free testosterone (relevant for both men and women)
• Estradiol, progesterone, FSH, LH
• SHBG (often reduced in insulin resistance, altering the bioavailability of sex hormones)

Inflammatory Markers

• High-sensitivity CRP (hsCRP)
• Homocysteine
• Ferritin
• Fibrinogen

Nutrient Status

• 25-hydroxyvitamin D: Vitamin D deficiency is extremely common in patients with obesity because adipose tissue sequesters vitamin D, reducing its bioavailability. Vitamin D deficiency is associated with insulin resistance, chronic inflammation, and impaired immune function.
• Magnesium (red blood cell magnesium provides a more accurate assessment than serum magnesium)
• Zinc, B12, folate, iron studies

Gut Health Assessment

• Comprehensive stool analysis with parasitology
• Organic acids testing (identifying microbial metabolites and assessing mitochondrial function)
• Intestinal permeability markers when leaky gut is suspected

Toxin Burden Assessment

• Heavy metals panel
• Environmental chemical panel when clinically indicated

This comprehensive evaluation allows me to build a detailed, individualized biological portrait of each patient, identify the specific drivers of their obesity, and guide a targeted, effective treatment plan that addresses the actual causes rather than merely managing downstream consequences.

Obesity Coding: The Administrative Foundation of Effective Clinical Care

Why Accurate Coding Is a Clinical and Ethical Imperative

The estimated annual cost of obesity in the United States is approximately $260 billion (Cawley et al., 2021). This staggering figure represents not just the direct medical costs of treating obesity and its complications but also the indirect costs of lost productivity, disability, and premature mortality. And embedded within this number is an important but underappreciated reality: this figure is almost certainly an underestimate, because obesity has historically been systematically undercoded, underdiagnosed, and undertreated in the American healthcare system.

When clinicians fail to code for obesity accurately, they contribute to a chain of consequences that ultimately harms patients:

• Obesity is absent from the patient’s documented medical record as an active, coded diagnosis, making it invisible to other providers and researchers
• Administrative and research databases that rely on diagnostic codes show artificially low rates of obesity, leading policymakers to underestimate the disease burden.
• Policymakers and payers use these underestimated data to make decisions about coverage, reimbursement, and resource allocation.n
• Research funding for obesity treatment is deprioritized relative to conditions that are coded more consistently.
• Reimbursement for obesity treatment remains inadequate because the data do not reflect the disease’s true burden.
• Patients with obesity receive less insurance coverage for evidence-based treatments.

Accurate obesity coding is therefore not merely an administrative exercise. It is an act of clinical advocacy and systemic accountability for patients with one of the most burdensome and undertreated chronic diseases in the world.

The October 2024 ICD-10 Update: What Changed and Why It Matters

In October 2024, the ICD-10-CM coding system underwent a significant update with profound implications for every clinician who cares for patients with obesity. This update reflected a fundamental shift in how obesity is conceptualized, labeled, and communicated within the healthcare system.

The key changes and their clinical significance include:

Improved Diagnostic Accuracy and Granularity

The updated codes provide a more nuanced framework for classifying obesity, allowing clinicians to capture the full spectrum of obesity severity, document associated complications more accurately, and distinguish between different etiologies of obesity with greater precision.

Stigma-Free, Person-Centered Language

Perhaps the most clinically and ethically significant change was the move away from stigmatizing terminology embedded in previous code descriptions. Before the October 2024 update, clinicians were constrained to use terms like “morbid obesity” or “obesity due to excess calories” in formal diagnostic coding, language that is both scientifically reductive and deeply stigmatizing.

A powerful illustration of the real harm this language causes involves a patient who came to a primary care clinic for mental health treatment and was recorded in her chart as having “morbid obesity due to excess calories.” When she subsequently reviewed her medical records through the patient portal, she was deeply offended and called the clinic to complain. Before the October 2024 update, the clinician had no alternative to that terminology. The updated codes now provide options for stigma-free, scientifically accurate labeling of obesity that reflects the disease’s complexity and treats patients with the dignity they deserve.

Supporting Non-Biased Clinical Documentation

The updated language in the ICD-10 codes aligns with the growing consensus in obesity medicine that obesity is a chronic, complex, multifactorial disease driven by genetic, biological, environmental, behavioral, and psychosocial factors; that it is not a personal failing or a simple consequence of poor choices; and that clinical documentation should reflect the complexity and dignity of the patient’s experience. The October 2024 revisions make it possible to document obesity accurately and compassionately within the official coding framework for the first time.

The E Code and Z Code Relationship: The Most Important Coding Rule in Obesity Medicine

One of the most practically important elements of the ICD-10 framework for obesity is the required pairing of E codes and Z codes. Understanding and consistently applying this relationship is essential for accurate billing and appropriate reimbursement.

E Codes: Classifying Obesity by Class

The E codes classify obesity by obesity class, which BMI determines:

• Class I Obesity: BMI 30.0 to 34.9 kg/m2
• Class II Obesity: BMI 35.0 to 39.9 kg/m2
• Class III Obesity: BMI 40.0 kg/m2 and above (previously labeled “morbid obesity,” a term that is now discouraged in clinical communication)

The E code establishes the primary diagnosis and identifies the class of obesity being treated.

Z Codes: Capturing the Specific BMI for Severity Documentation

The Z codes for BMI provide a quantitative measure of severity that must accompany the E code. The Z code documents the patient’s specific BMI value, which:

• Confirms and supports the obesity class being coded
• Influences risk adjustment calculations used by payers to determine reimbursement levels
• Documents the severity of the condition in the medical record, supporting the medical necessity of the treatment plan
• Provides data for research and population health analysis

The Cardinal Rule: Always Use E Codes and Z Codes Together

Never document an obesity E code without a corresponding Z code. Documenting an obesity diagnosis without the BMI code is administratively incomplete and may result in claim denial or reduced reimbursement. It also fails to document the condition’s specific severity, which is clinically and prognostically significant.

In practice, every time an obesity diagnosis is documented, the following steps must be completed:

1. Measure the patient’s height and weight using calibrated, appropriately sized equipment
2. Calculate the BMI (most EHR systems do this automatically)
3. Assign the appropriate E code based on the obesity class
4. Assign the corresponding Z code based on the specific BMI value
5. Document both codes in the patient’s record and on the billing claim

Pediatric Obesity Coding: Age and Gender-Specific BMI Percentiles

Obesity in children and adolescents requires a fundamentally different framework from adult obesity coding because BMI is highly age-dependent and sex-dependent in growing children. A BMI value that would indicate obesity in a 40-year-old adult may be entirely appropriate for a 10-year-old child.

For pediatric patients aged 2 to 18 years, the updated ICD-10 codes use age- and sex-specific BMI percentiles consistent with CDC growth chart methodology:

• Healthy weight: 5th to less than 85th percentile
• Overweight: 85th to less than 95th percentile
• Obesity: 95th percentile or greater
• Severe obesity: 120% of the 95th percentile or greater, or BMI 35 kg/m2 or greater (whichever is lower)

Step-by-step protocol for pediatric obesity coding:

1. Measure height and weight using calibrated equipment with standardized techniques
2. Calculate BMI (kg/m2)
3. Plot the BMI on age- and sex-specific CDC growth charts
4. Determine the BMI percentile and classify accordingly
5. Assign the pediatric obesity E code
6. Assign the corresponding age- and sex-specific Z code for BMI percentile
7. Document both codes together

The physiological basis for this classification system reflects the developmental plasticity of the hypothalamus and appetite regulation circuits in childhood: early obesity can alter the set point of hypothalamic appetite regulation in ways that persist into adulthood, making early identification, coding, and treatment of pediatric obesity a public health priority of the highest order.

Primary Versus Secondary Coding for Obesity: A Practical Decision Framework

One of the most practically important decisions in obesity coding is whether to code obesity as the primary diagnosis (the main reason for the visit) or as a secondary diagnosis (a coexisting condition that influences treatment but is not the primary focus of the encounter). This decision has significant implications for reimbursement, documentation requirements, and the clinical framing of care.

When to Code Obesity as the Primary Diagnosis

Obesity should be coded as the primary diagnosis when:

• The patient’s main reason for the visit is obesity management, such as in a dedicated obesity clinic visit, a visit for initiation or adjustment of anti-obesity medication, or a visit specifically scheduled to address weight management and its complications
• The primary focus of the clinical encounter is the assessment, treatment, and monitoring of obesity as the central health issue
• The clinician spends the majority of time addressing obesity and its direct management (relevant to time-based billing)

When to Code Obesity as a Secondary Diagnosis

Obesity should be coded as a secondary diagnosis when:

• The patient comes in for management of a specific comorbid condition, such as hypertension, type 2 diabetes, or knee osteoarthritis, and that condition is the primary reason for the visit
• The primary focus of the encounter is medication management or lab review for a condition other than obesity
• Obesity is documented as a contributing factor to the primary condition being treated

The Problem of Chronic Underuse of Obesity as a Primary Diagnosis

Historically, there has been a well-documented tendency among clinicians to underprioritize obesity coding, particularly as a primary diagnosis. This has been driven by inadequate reimbursement for obesity treatment in the past, lack of awareness of available codes, discomfort among some clinicians with directly addressing obesity as the primary clinical issue, time constraints in busy primary care settings, and patient reluctance to have obesity prominently documented due to stigma or insurance concerns. The October 2024 update’s stigma-free language and improved coding options directly address several of these barriers.

Medical Billing and Coding for Obesity: Building a Financially Sustainable Practice

The Two Pathways for E/M Billing: Time and Medical Decision-Making

To build a practice that can deliver the frequent, high-touch, multifaceted care patients with obesity need, every provider must have a firm grasp of Evaluation and Management (E/M) billing. E/M codes are the language we use to communicate the value and complexity of the cognitive work we perform for our patients. The American Medical Association (AMA) establishes two distinct pathways for determining the appropriate E/M code: billing based on total time spent on the date of the encounter, or billing based on the complexity of Medical Decision-Making (MDM).

In my integrative practice, where sessions often involve extensive counseling, education, lifestyle coaching, complex medication management, and multisystem coordination, I find both methods have their place. Time-based billing is often most accurate for counseling-heavy visits, while MDM-based billing better captures the value of visits involving complex diagnostic and therapeutic decision-making even when total time is modest.

New Versus Established Patient Codes: A Critical Distinction

The CPT code set distinguishes between new patients (those who have not received professional services from the same provider or group practice specialty within the past three years) and established patients. New patient visits are reimbursed at higher rates because they require more comprehensive data collection, history-taking, and care plan establishment.

Outpatient E/M Code Reference

New Patient Codes:

• 99202: 15-29 minutes total time
• 99203: 30-44 minutes total time
• 99204: 45-59 minutes total time
• 99205: 60-74 minutes total time

Established Patient Codes:

• 99212: 10-19 minutes total time
• 99213: 20-29 minutes total time
• 99214: 30-39 minutes total time
• 99215: 40-54 minutes total time

When total time exceeds the upper limit of the highest-level code (74 minutes for new patients, 54 minutes for established patients), prolonged service codes capture additional time in 15- to 16-minute increments. These are frequently applicable in comprehensive obesity evaluations.

Mastering Time-Based Billing: What Counts and How to Document It

The 2021 AMA revisions to E/M coding dramatically expanded the flexibility of time-based billing by removing the requirement that more than half of visit time be spent on counseling and coordination of care, and by allowing all clinician activities on the date of service to count toward total time. This was a landmark change for clinicians in obesity medicine, where the cognitive work extends far beyond the face-to-face encounter.

Components of Billable Time Under Current Guidelines

Before the Visit (Pre-Encounter Preparation):

• Comprehensive chart review: Reviewing past medical history, prior laboratory results, imaging studies, specialist consultation notes, functional medicine test results, and previous provider notes. This preparatory work is essential for providing efficient, high-quality care and is fully billable.
• Prior documentation review: Reviewing prior records from other practices or hospitals.

During the Visit:

• History and physical examination: Including all face-to-face time with the patient and any family members or caregivers.
• Developing the treatment plan: This is often the most time-consuming element, including explaining diagnoses, discussing medication options with full risk-benefit counseling, providing dietary and activity prescriptions, and collaboratively establishing patient goals.
• Patient education and counseling: Explain the chronic disease model of obesity, discuss the physiology of weight regulation, and coach behavioral strategies.
• Ordering tests: Discussing the rationale for laboratory, imaging, or functional medicine testing with the patient.

After the Visit:

• Documentation: Completing the clinical note, which must accurately reflect the history, examination, clinical reasoning, and time attestation.
• Placing orders: Formally submitting laboratory, imaging, and medication orders.
• Care coordination: Communicating with other providers, writing referral letters, discussing cases with team members.
• Results review: Reviewing laboratory or imaging results that arrive on the same date as the visit.
• Administrative tasks: Completing prior authorization forms, clinical documentation for insurance purposes.

Sample Time Attestation Statement

At the end of every time-based billing note, I include a clear attestation statement:

“I spent a total of 33 minutes on August 18, 2026, on the care of this patient. This time was spent as follows: chart review and pre-visit preparation, 3 minutes; history, examination, and ordering discussion, 5 minutes; treatment plan development and behavioral counseling, 20 minutes; documentation and care coordination, 5 minutes. Total time: 33 minutes.”

This total of 33 minutes corresponds to CPT code 99214 for an established patient visit (30-39 minutes). The itemized documentation creates a robust, compliant, and defensible record.

Medical Decision-Making (MDM): The Three Elements and the Level 4 Rule

For encounters billed by MDM, the appropriate E/M code level is determined by the complexity across three core elements, with the code level set by the highest level achieved in at least two of the three elements:

Element 1: Number and Complexity of Problems Addressed

In obesity care, this element is frequently at the moderate to high complexity level because:

• Obesity itself, when active and associated with complications, is classified as a chronic illness with exacerbation or progression
• Most patients with obesity present with multiple comorbidities (diabetes, hypertension, OSA, osteoarthritis) that each require simultaneous assessment and management

Element 2: Amount and Complexity of Data Reviewed and Analyzed

In obesity care, the data element is typically substantial, including:

• Reviewing laboratory results (metabolic panels, thyroid function, hormonal assays, inflammatory markers)
• Reviewing imaging studies (body composition assessments, abdominal ultrasound for NAFLD evaluation)
• Reviewing external records from specialists or prior providers
• Independent interpretation of diagnostic tests

Element 3: Risk of Complications and Management Decisions

The prescription drug management decision is the most commonly applicable high-risk element in obesity care. The decision to initiate, adjust, or discontinue a prescription medication, including anti-obesity medications, is classified as a moderate-risk management decision, which typically supports a Level 4 code.

The Level 4 Rule of Thumb

My practical heuristic for MDM coding in obesity medicine: I begin from an assumption of a Level 4 visit (99204 for new patients, 99214 for established patients) whenever the visit involves:

• Ordering diagnostic tests such as laboratory panels, imaging, or functional assessments
• Making any prescription drug management decision (initiating, adjusting, or discontinuing a medication)
• Managing a chronic illness with exacerbation, progression, or treatment-related complications

I then confirm by checking all three MDM elements to ensure at least two qualify at the moderate or high complexity level.

An Important MDM Distinction: Work Outside the Date of Service

One of the most provider-friendly features of MDM-based billing is that it allows clinicians to count cognitive work that occurs outside the date of service. For example, if laboratory results arrive two days after a patient visit and require a telephone call to adjust medication, the cognitive effort of reviewing and acting on those results can contribute to the MDM of the original visit. This contrasts with time-based billing, which is strictly limited to activities performed on the date of service.

Clinical Case Example: MDM in Practice

Consider a 45-year-old established female patient who presents for follow-up in our obesity management program. She reports persistent nausea, constipation, and reduced appetite that began one week after we increased the dose of her GLP-1 receptor agonist. Her abdominal examination is soft with mild diffuse tenderness but no acute findings. We:

1. Diagnose drug-induced constipation as a complication of the GLP-1 medication
2. Provide patient education on fiber intake, hydration, and activity
3. Recommend an over-the-counter stool softener
4. Make the prescription drug management decision to reduce her GLP-1 dose back to the previously tolerated level and transmit an updated prescription to her pharmacy

Applying the MDM framework:

• Problem complexity: Moderate (chronic illness with treatment side effect requiring active management)
• Data complexity: Low (no new laboratory or imaging ordered; exam findings reviewed)
• Risk: Moderate (prescription drug management decision made)

Two of three elements at the moderate level support CPT code 99214, even if this visit lasted only 15 minutes. The complexity of the decision, not the duration, drives the code.

Specialized Billing Services: Expanding the Scope of Reimbursable Obesity Care

Beyond standard E/M visits, several specialized billing pathways allow practices to capture the full value of comprehensive, high-frequency obesity management:

Service Category	Primary Payer	Associated Codes
Intensive Behavioral Therapy (IBT)	Medicare	G0447, G0473
Preventative Counseling	Commercial Insurance	99401-99404
Chronic Care Management (CCM)	Medicare	99490, 99439, 99491, 99487, 99489
Remote Patient Monitoring (RPM)	Medicare and Commercial	99453, 99454, 99457, 99458

Medicare Intensive Behavioral Therapy (IBT) for Obesity

Medicare’s Intensive Behavioral Therapy (IBT) benefit reimburses providers for the behavioral change interventions needed for sustained weight loss. This is critically important: IBT is not an E/M service. It does not require a history of present illness, a review of systems, or a physical examination. The focus must be exclusively on the “how-to” of behavioral change: nutrition habits, physical activity behaviors, self-monitoring, meal planning, and stress-related eating patterns.

Eligibility and Frequency

• Eligible patients: Medicare beneficiaries with BMI ? 30 kg/m2
• Billing codes: G0447 (one-on-one, 15 minutes), G0473 (group, 2-10 patients, 30 minutes)
• Allowed frequency:

• One visit every week for the first month
• One visit every two weeks for months 2-6
• One visit per month for months 7-12 (conditional on achieving at least 3 kg of weight loss)

Documentation Requirements for IBT

IBT documentation must reflect the behavioral focus of the session. Appropriate content includes:

• “Discussed patient’s daily calorie and macronutrient goals (1,500 kcal, 100g protein target).”
• “Introduced the plate method as a visual tool for portion control: half non-starchy vegetables, quarter lean protein, quarter complex carbohydrate”
• “Reviewed food log; identified pattern of late-night snacking associated with stress; brainstormed alternative coping strategies”
• “Discussed strategies for establishing consistent meal timing to support circadian alignment”
• “Set progressive step-count goal for the upcoming two weeks using a pedometer”

Leveraging the Clinical Team for IBT

IBT visits can be delegated to qualified ancillary staff (RNs, certified health coaches) under the billing provider’s direct supervision. The billing provider must be physically present in the office suite, though not necessarily in the same room. This delegation capacity is invaluable for scaling a high-frequency obesity management program without overextending physician or NP time.

Preventive Counseling for Commercial Insurance Patients

For patients with commercial insurance, the parallel service to Medicare’s IBT is found in the preventive screening and counseling codes (CPT 99401-99404), which are designed for counseling on risk factors and behavior change:

• 99401: Approximately 15 minutes
• 99402: Approximately 30 minutes
• 99403: Approximately 45 minutes
• 99404: Approximately 60 minutes

These visits are structured identically to IBT visits, focusing on behavioral aspects (nutrition, physical activity, lifestyle modification) without delving into medical diagnoses or medication management. A critical operational distinction: preventive counseling cannot be billed on the same day as a standard E/M visit even with a -25 modifier. These must be standalone visits on separate days, making them ideal for the “in-between” weeks in a high-frequency care model.

Like IBT, preventive counseling visits can be delegated to ancillary staff (RNs, health coaches) under supervision, enabling high-volume behavioral support without requiring direct provider time for every session.

A Note on Reimbursement Variability

I strongly recommend verifying coverage for these specific codes with each payer before scheduling. Not all commercial plans reimburse for 99401-99404, or they may impose specific limitations. Running eligibility checks for these codes when new patients establish care, and using a notice of non-covered services form (analogous to Medicare’s Advance Beneficiary Notice) when coverage is uncertain, prevents surprise billing and proactively manages patient expectations.

Medicare Chronic Care Management (CCM)

Chronic Care Management (CCM) is a Medicare program that compensates providers for the extensive non-face-to-face care coordination complex patients with multiple chronic conditions require between visits. For any provider who has ever spent 20 minutes after clinic hours reviewing a patient’s lab results, calling a specialist, adjusting a medication, and updating a care plan without any reimbursement, CCM represents a long-overdue recognition of the value of this work.

Eligibility

Medicare patients with two or more chronic conditions expected to last at least 12 months or until the end of life. For our obesity patient population, this is the vast majority: a patient with obesity and hypertension, or obesity and type 2 diabetes, qualifies. An estimated two-thirds of all Medicare beneficiaries meet CCM eligibility criteria.

Core Requirement

Create and regularly maintain a comprehensive care plan that addresses the patient’s problems, treatment goals, interventions, and symptom management strategies.

CCM Code Structure

CPT Code	Description	Time Requirement	Delegation
99490	Primary CCM Code	First 20 minutes of clinical staff time per calendar month	Can be delegated to RN, LPN, MA, health coach
99439	Add-on for 99490	Each additional 20 minutes of staff time	Can be delegated
99491	Physician/QHP-led CCM	First 30 minutes of provider time	Cannot be delegated
99487	Complex CCM	First 60 minutes of clinical staff time	Can be delegated
99489	Add-on for 99487	Each additional 30 minutes of staff time	Can be delegated
CCM provides the framework for maintaining the additional touchpoints that keep patients with complex obesity engaged with their treatment plans between office visits, supporting the high-frequency contact model that evidence consistently shows improves outcomes.

Remote Patient Monitoring (RPM): Technology-Enabled Proactive Care

Remote Patient Monitoring (RPM) is an area of healthcare I find particularly exciting for obesity management. The ability to gather objective, real-time physiological data from patients at home transforms chronic disease management from isolated monthly snapshots into a continuous, responsive clinical relationship.

In our clinic, our primary RPM tool is the 5G-enabled smart scale. When a patient steps on the scale at home, the scale automatically transmits their weight to a secure dashboard integrated with our EHR. This gives us real-time visibility into weight trends between appointments, allowing us to celebrate momentum, identify plateaus early, and intervene promptly when a concerning pattern emerges, rather than waiting a month to discover that a patient has been struggling silently.

We also use RPM-connected blood pressure monitors for patients with hypertension and obesity, continuous glucose monitors (CGMs) through collaborative medical oversight with Dr. Cardenas for patients with diabetes or insulin resistance, and, in some cases, heart rate variability monitors to track autonomic balance and stress response.

Non-Negotiable RPM Requirements

1. FDA-approved device: The monitoring device must be FDA-approved for medical use. Consumer-grade devices patients purchase independently do not meet this requirement.
2. Practice-paid device: The practice must pay for the RPM device, not the patient. The practice provides the device as part of the RPM service.

RPM Billing Structure

CPT Code	Description	Requirement
99453	Initial setup and patient education	One-time billing per patient per device type
99454	Device supply and data transmission	Must include at least 16 days of data over 30 days
99457	Treatment management services (first 20 minutes)	20 minutes of clinical staff, physician, or QHP time per month
99458	Additional treatment management	Each additional 20 minutes per month
RPM billing for the setup, monthly data monitoring, and staff time spent communicating with patients about their data creates a reimbursable, proactive, continuous care model that is demonstrably more effective than monthly office visit-only care for chronic disease management.

Building a Six-Month Obesity Management Care Plan: The Weekly Touchpoint Model

The Evidence for High-Frequency Contact in Obesity Treatment

One of the most consistently replicated findings in obesity treatment research is the link between visit frequency and weight-loss outcomes. The Look AHEAD (Action for Health in Diabetes) trial, the largest randomized controlled trial of intensive lifestyle intervention in patients with type 2 diabetes and obesity, demonstrated that an intensive lifestyle intervention producing an average weight loss of 8.6% at one year significantly improved glycemic control, blood pressure, triglycerides, and physical fitness (Look AHEAD Research Group, 2013). The intensive intervention arm averaged 42 contacts in the first year, compared to approximately four contacts in the usual care arm.

The Obesity Medicine Association’s clinical guidelines similarly identify approximately 16 visits in the first year as associated with meaningfully improved outcomes, with higher-frequency early contact being particularly important for establishing behavioral momentum and preventing early regression.

The structure I am about to describe is not designed primarily around billing optimization. It is designed around the visit frequency that evidence shows produces the best clinical outcomes, which happens to also be supportable within existing billing frameworks for both Medicare and commercial insurance patients.

Six-Month Care Plan for Commercial Insurance Patients

Month 1: Establishing the Foundation

• Week 1: Initial E/M Visit (CPT 99204): Comprehensive initial consultation with Dr. Cardenas or me covering the full history, physical examination, functional assessment, laboratory orders, and development of the initial individualized care plan. This visit establishes the diagnosis of obesity with appropriate E code and Z code, identifies comorbidities, assesses readiness for change, and creates the foundation for all subsequent interventions.
• Week 2: Preventive Counseling Visit (CPT 99401): A separate, 15-minute visit with our RN or health coach focused entirely on implementing the initial nutritional goals established in Week 1. Specific topics: meal timing, protein targets, anti-inflammatory food choices, and practical meal preparation strategies.
• Week 3: RPM Setup and Education (CPT 99453): The patient receives their RPM device (smart scale and/or blood pressure monitor), and our staff provides thorough education on its use, including standardized measurement technique and what to do if readings are concerning.
• Week 4: Preventative Counseling Visit (CPT 99401): A 15-minute behavioral session covering physical activity initiation: starting with manageable movement goals, tracking steps, and identifying practical activity opportunities.
• End of Month 1: Bill for RPM data transmission (99454) and RPM management (99457) if 16 days of data have been transmitted and 20 minutes of staff management time has been logged.

Months 2 Through 6: The Sustained Rhythm

Each month follows a consistent pattern:

• First week of the month: Follow-up E/M Visit (CPT 99214 or 99213): A 20-30 minute visit with Dr. Cardenas or me to review metabolic progress, manage medications, interpret laboratory results, and adapt the treatment strategy based on the patient’s response.
• Remaining weeks: Biweekly Preventative Counseling Visits (CPT 99401): These 15-minute behavioral sessions with the health coach or RN focus on executing the plan established at the monthly E/M visit, troubleshooting challenges, reinforcing progress, and building behavioral skills.
• Monthly: RPM billing (99454, 99457): Continued monthly billing for data transmission and staff management time based on ongoing remote monitoring.

This structure creates at least one clinical touchpoint every week for six months, a frequency supported by evidence for meaningful, sustained behavior change in chronic disease management.

Six-Month Care Plan for Medicare Patients

Month 1: The Intensive Phase

• Week 1: Initial E/M Visit (CPT 99204)
• Week 2: IBT Visit (G0447): 15-minute one-on-one behavioral session with RN focused on nutritional behavior
• Week 3: IBT Visit (G0447): 15-minute session focused on physical activity behavior and self-monitoring
• Week 4: IBT Visit (G0447): 15-minute session focused on stress management and sleep hygiene strategies
• Throughout Month 1: Bill for CCM (99490) for the 20 minutes of non-face-to-face care coordination (care plan maintenance, care communications, lab result management), RPM setup (99453, 99454, 99457) as applicable

Months 2 Through 6: Sustained Support

Each month:

• Biweekly IBT visits (G0447): Continued behavioral sessions per Medicare’s allowed frequency
• Monthly E/M follow-up visit (CPT 99214): Medical management, medication adjustments, and metabolic monitoring. Schedule IBT and E/M visits on different days to maintain clear billing separation.
• Monthly CCM billing (99490) for continued non-face-to-face care coordination
• Monthly RPM billing (99454, 99457) for continued remote monitoring

This structure creates a comprehensive, financially sustainable, and clinically robust care model that provides the contact frequency evidence supports while operating within existing billing frameworks.

Personal Injury and Obesity: The Complex Clinical Intersection

How Obesity Complicates Personal Injury Care

At Injury Medical Clinic PA, a significant portion of our patient population includes individuals recovering from personal injuries, including motor vehicle accidents, workplace injuries, slip-and-fall incidents, and sports injuries. Patients with obesity who sustain personal injuries face a uniquely challenging set of physiological circumstances that require specialized integrative care.

Amplified and Prolonged Inflammatory Response

Obesity is characterized by chronic low-grade systemic inflammation. When a patient with obesity sustains a traumatic injury, the pre-existing inflammatory burden is added to the acute inflammatory response triggered by the trauma. The result is an amplified and prolonged inflammatory cascade that:

• Increases pain severity and pain duration following injury
• Slows tissue healing by impairing the normal progression through the inflammatory, proliferative, and remodeling phases of repair
• Increases the risk of complications including delayed healing, increased infection risk, and greater likelihood of transitioning from acute to chronic pain
• Promotes central sensitization, in which sustained peripheral nociceptive input produces lasting changes in central pain processing pathways

Greater Musculoskeletal Vulnerability

Patients with obesity have greater baseline musculoskeletal vulnerability than healthy-weight individuals. They are more likely to:

• Experience more severe injuries from equivalent trauma forces due to greater kinetic energy and altered biomechanics
• Sustain joint injuries complicated by the additional mechanical load of excess body weight
• Develop chronic musculoskeletal pain following injury due to the inflammatory environment
• Have longer rehabilitation timelines and delayed functional recovery

Psychosocial Complications

Personal injuries frequently produce significant psychosocial consequences, including post-traumatic stress disorder (PTSD) or PTSD-related symptoms, depression, anxiety, sleep disruption, financial stress, and reduced independence. For patients with obesity, these psychosocial stressors add to an already elevated psychological burden, and the resulting cortisol elevation can further worsen metabolic dysfunction and impede healing.

The Integrative Approach to Personal Injury Care in Patients With Obesity

Our protocol for patients managing both personal injury and obesity is phased and carefully integrated:

Phase 1: Acute Injury Management (Weeks 1 through 4)

• Cardenas conducts a comprehensive medical evaluation to assess injury severity, rule out serious complications, manage acute pain appropriately, and coordinate with emergency or specialist care as needed.
• I provide chiropractic acute care, including gentle spinal manipulation, soft-tissue therapies, and therapeutic modalities (ice/heat, electrical stimulation, therapeutic ultrasound) to reduce pain and inflammation. I  initiate anti-inflammatory nutritional support with high-dose omega-3 fatty acids, curcumin, bromelain, and magnesium to reduce the inflammatory burden without suppressing necessary tissue repair.
• Clinical documentation of the injury and its functional impact supports personal injury legal claims when applicable.

Phase 2: Sub-Acute Rehabilitation (Weeks 4 through 12)

• Progressive rehabilitation introduces active exercises beginning with low-load, low-impact activities and advancing as function improves.
• Spinal stabilization and core strengthening are prioritized for patients with spine injuries, as a strong core reduces spinal loading and pain.
• Functional medicine support continues with anti-inflammatory nutritional protocols, gut microbiome support, and management of underlying metabolic conditions that impede recovery.
• Cardenas adjusts medications as the patient’s condition evolves and evaluates appropriateness for anti-obesity medications.

Phase 3: Long-Term Recovery and Obesity Management Integration (3 through 12 Months)

• Sustained rehabilitation and progressive exercise build toward the 150 to 300 minutes per week of moderate-intensity activity recommended for long-term obesity management.
• Full functional medicine obesity management protocols are implemented to address the specific biological drivers identified in the initial evaluation.
• Ongoing chiropractic maintenance care supports spinal alignment, joint mobility, and nervous system function as the patient increases physical activity.
• Continued collaborative medical management by Dr. Cardenas maintains oversight of comorbidities and pharmacological treatment.

Practice Models for Obesity Care: Configurations for Different Clinical Settings

Model One: Dedicated Obesity Appointments Within an Existing Practice

This is the most accessible entry point for most clinicians. By blocking obesity-specific appointment slots within an existing practice schedule, typically 45 to 60 minutes for initial visits and 20 to 30 minutes for follow-ups, it is possible to deliver meaningful obesity care without building a separate program. The key operational requirement is not squeezing obesity discussions into the margins of unrelated visits. Dedicated time creates the space for thorough history-taking, personalized plan development, and the behavioral counseling that is the cornerstone of effective obesity management.

Model Two: Internal Obesity Program Within a Broader Practice

Designating specific clinic sessions (for example, Wednesday afternoons) as an “obesity clinic” allows staff expertise, specialized equipment, and programmatic resources to concentrate, improving both efficiency and patient experience. Many practices find that this designated structure naturally expands as demand grows, creating a self-sustaining program within the broader practice.

Model Three: Standalone Obesity Clinic

A dedicated obesity service line with its own scheduling, staff, equipment, and program structure represents the highest investment and the highest capacity for comprehensive, longitudinal obesity care. Telehealth and hybrid care delivery are essential components of this model, extending access to patients with transportation or scheduling barriers and providing the between-visit touchpoints that sustain engagement.

Model Four: Referral-Centric Approach With Structured Follow-Up

When internal resources are limited, referring patients to qualified obesity specialists remains clinically appropriate. The critical principle is that referral is not discharge: always confirm patient engagement with the referred specialist, troubleshoot barriers to follow-through, and schedule a follow-up visit to support adherence to recommendations.

Appointment Structure and Clinical Workflows: From Intake to Maintenance

Intake and History and Physical (45 to 60 Minutes)

The initial obesity evaluation is the most time-intensive and clinically critical encounter in the care pathway. The history must capture:

• Weight trajectory: Lifetime weight history, age of onset, prior treatment attempts, previous medications
• Dietary patterns: Current eating habits, food preferences, cultural food traditions, barriers to healthy eating
• Physical activity history: Current activity level, prior activity patterns, musculoskeletal limitations
• Sleep: Duration, quality, symptoms of OSA, chronotype and circadian patterns
• Stress and psychosocial context: Life stressors, social support, mental health history, ACEs
• Medications: Comprehensive medication review with attention to agents that cause weight gain
• Medical history: All comorbidities and their current management status
• Readiness to change: Motivational assessment, prior barriers to success, patient values and goals

Laboratory orders at the initial visit include (as clinically indicated): fasting glucose and insulin, HbA1c, lipid panel, liver enzymes (AST, ALT), TSH with free T4 and free T3, 25-hydroxyvitamin D, CBC, comprehensive metabolic panel, hsCRP, and a sleep apnea screening questionnaire.

The physical examination focuses on cardiometabolic risk assessment, joint mechanics evaluation, postural analysis, gait assessment, and identifying pain generators.

Week 2: Lab Review and Plan Initiation (30 to 60 Minutes)

Review laboratory findings with the patient in the context of their clinical presentation and goals. Establish:

• Weight and metabolic goals: Framed in terms of health improvements (blood pressure, A1c, pain reduction, sleep quality) rather than exclusively scale weight
• Personalized nutritional framework with specific, actionable starting guidance
• Movement prescription based on baseline mobility, pain, and functional capacity
• Medication plan: Initiate pharmacotherapy when indicated; adjust or discontinue medications that contribute to weight gain
• Monitoring plan: Define follow-up cadence, data to track, and alert thresholds for safety

Weeks 3 Through 4: Weekly Follow-Ups (20 to 30 Minutes)

These early, frequent visits are the most critical for establishing momentum and identifying and resolving barriers before they become entrenched. Focus:

• Fine-tune nutrition plan based on adherence and tolerance
• Progress exercise load within pain and recovery limits
• Titrate medications based on tolerability and early response data
• Reinforce behavioral strategies and address emerging challenges

Weeks 5 Through 10: Biweekly Follow-Ups

As the treatment plan stabilizes, follow-up frequency decreases to biweekly. Focus shifts to:

• Consolidating habits established in the intensive early phase
• Expanding movement diversity and gradually increasing exercise intensity
• Integrating social supports (group education, community walking programs)
• Continued bias-free reinforcement and problem-solving

Months 3 Through 12: Maintenance and Relapse Prevention

As stability improves, follow-up moves from biweekly to monthly or every six to eight weeks. The core of maintenance care involves:

• Relapse normalization: Explicitly explaining the biological and environmental pressures that drive weight regain, so that patients interpret a plateau or temporary regression as a signal to engage the rescue plan rather than evidence of personal failure
• Pre-defined rescue protocols: Specific, agreed-upon steps (increase visit frequency, adjust medications, re-engage coaching) that the patient and I have planned together in advance
• Flexible goal evolution: Shifting from weight-centric metrics to function, energy, pain levels, sleep quality, and broader healthspan markers as the patient’s progress stabilizes

Monitoring and Outcomes: What We Track and Why

A comprehensive obesity management program requires systematic outcome tracking across multiple dimensions to ensure interventions are working, safety is maintained, and the care plan adapts as the patient’s status evolves.

Anthropometric and Body Composition Metrics

• Weight, BMI, and waist circumference at every visit (essential for Z code accuracy and trend monitoring)
• Body composition (lean mass vs. fat mass) when technology is available, using DEXA, bioelectrical impedance, or air displacement plethysmography

Metabolic Markers

• HbA1c and fasting glucose (every 3 months in the first year, then every 6 months when stable)
• Fasting insulin and HOMA-IR (to track insulin resistance trajectory)
• Lipid panel (every 6 months)
• Liver enzymes (every 6 months in patients with NAFLD)
• Blood pressure at every visit

Functional Outcomes

• 6-minute walk test: A simple, validated measure of functional capacity that tracks the impact of our interventions on physical performance
• Sit-to-stand test: A marker of lower extremity strength and functional independence
• Range of motion assessments at affected joints
• Numeric pain rating scale for all pain sites

Psychosocial and Behavioral Metrics

• Sleep quality (Pittsburgh Sleep Quality Index or similar validated tool)
• Stress and mood (PHQ-9 for depression, GAD-7 for anxiety)
• Physical activity logs and step counts
• Session attendance and treatment adherence

Safety Signals

• Hypoglycemia incidents (especially when initiating GLP-1 receptor agonists alongside existing diabetes medications)
• Orthostatic symptoms (relevant when initiating medications that may affect blood pressure)
• Adverse medication effects and tolerance
• Pain flare-ups or new musculoskeletal complaints

The Social Determinants of Health and Culturally Competent Obesity Care

Obesity Is Not Just a Clinical Problem

Any comprehensive approach to obesity must acknowledge the profound role of social determinants of health (SDOH) in both the development and management of the disease. In El Paso, Texas, where our clinic serves a predominantly Hispanic community with high rates of poverty, food insecurity, and limited access to specialty healthcare, these social determinants are not background factors. They are central clinical realities that shape every treatment decision.

SDOH factors with direct relevance to obesity include:

• Food environment: Access to affordable, nutritious food versus food deserts or food swamps with abundant unhealthy options and limited healthy choices
• Physical activity environment: Access to safe spaces for physical activity, including parks, sidewalks, recreation centers, and fitness facilities that are safe to use
• Socioeconomic status: Poverty is strongly associated with obesity through the intersection of food insecurity, chronic stress, limited healthcare access, and environmentally constrained lifestyle choices
• Racial and ethnic disparities: Obesity rates are disproportionately high in certain racial and ethnic groups in the United States, reflecting the cumulative effects of systemic racism, historical trauma, and inequitable access to resources
• Adverse childhood experiences (ACEs): Strongly associated with obesity through HPA axis dysregulation, emotional eating, and reduced self-regulatory capacity

Culturally Competent Obesity Care in a Border Community

Effective obesity care for the patient population we serve requires:

• Cultural humility and respect: Genuinely listening to and respecting cultural differences in attitudes toward body weight, food, family dynamics, and healthcare
• Culturally appropriate nutritional counseling: Building dietary recommendations around familiar, culturally meaningful foods and culinary traditions rather than imposing a culturally foreign dietary pattern
• Bilingual and bicultural services: Providing care and educational materials in the patient’s preferred language, with truly bicultural (not just translated) health education
• Community partnerships: Engaging with community organizations, faith communities, local schools, and neighborhood resources to extend the reach of health promotion beyond the clinic walls
• Food insecurity navigation: Proactively connecting patients with food assistance programs and identifying community resources for healthy food access when food insecurity is identified

Evidence-Based Guidelines Anchoring Our Clinical Practice

Our clinical protocols are explicitly grounded in the highest-quality available guidance from leading professional organizations:

• Obesity Medicine Association (OMA): The Adult Obesity Algorithm and Obesity Pillars clinical practice statements provide pragmatic, comprehensive frameworks integrating behavioral, nutritional, pharmacological, and systems approaches to obesity management (Kahan & Manson, 2019).
• American Association of Clinical Endocrinology (AACE/ACE): The comprehensive clinical practice guidelines emphasize a complications-centric approach to obesity management, stratifying treatment intensity based on the presence and severity of obesity-related complications rather than BMI alone (Garvey et al., 2016).
• American Gastroenterological Association (AGA): Clinical practice guidelines on pharmacological interventions inform medication selection and endoscopic treatment options for obesity with GI comorbidities (AGA, 2022).
• Endocrine Society: Clinical practice guidelines on pharmacological management of obesity define indications, monitoring requirements, and safety parameters for anti-obesity medications (Apovian et al., 2015).
• AHA/ACC/TOS Guideline: Foundational cardiovascular risk framing for overweight and obesity management and lifestyle therapy integration (Jensen et al., 2014).

These evidence sources anchor every protocol, inform risk stratification, guide pharmacotherapy decisions, and underscore the chronic disease model that underpins our integrative approach.

Payment Structures: Insurance-Based, Self-Pay, and Hybrid Models

Insurance-Based Care

Advantages: Broader patient access; patients benefit from covered services without high out-of-pocket costs.

Challenges: Requires significant administrative infrastructure for claim management; potential for claim denials or policy changes; coverage variability across payers and plans (some commercial plans exclude primary obesity treatment or cap visit frequency at 6 to 8 per year); potential for policy-based clawbacks of previously paid claims.

Strategy: Use precise documentation with appropriate ICD-10 obesity and comorbidity codes; invest in pre-authorization workflows; proactively educate patients on coverage limitations; use telehealth, group visits, and asynchronous communication to maintain contact frequency within payer-imposed visit limits.

Self-Pay Care

Advantages: Appointment length and frequency align with clinical need rather than payer restrictions; streamlined operations with no claim-processing delays; flexible program design enabling bundled, programmatic care with group education, coaching, and monitoring.

Challenges: Financial barriers reduce health equity; transparent, accessible pricing is required; sliding-scale or reduced-fee options may be needed to serve economically diverse patient populations.

Self-Pay Package Structure:

• Initial bundle: Comprehensive H&P, functional medicine intake, body composition assessment, laboratory ordering and interpretation, initial nutrition and physical activity plan, behavioral readiness assessment, two follow-up visits, and access to group education
• Continuation bundle: Monthly subscription covering defined visit frequency, group sessions, remote monitoring review, and asynchronous messaging
• A la carte options: Individual chiropractic visits, rehabilitation sessions, dietitian consultations, health coaching, and specialized functional testing

Hybrid Model

The approach we use most frequently at Injury Medical Clinic PA: insurance billing covers medically necessary physician and NP visits, laboratory services, and pharmacotherapy; a modest program fee covers structured group education, specialized educational materials, coaching platform access, and certain non-covered services. This model maximizes access while maintaining the program depth needed for meaningful outcomes.

Ethical and Legal Considerations in Integrative Obesity Practice

Operating an integrative multidisciplinary practice requires rigorous attention to ethical and legal standards:

• Informed consent: Every intervention, medication, and procedure requires thorough informed consent with clear discussion of risks, benefits, and alternatives. Patients must be active, informed participants in all clinical decisions.
• Scope of practice compliance: All team members operate strictly within their professional scope of practice, with collaborative agreements between Dr. Cardenas and me that meet all Texas regulatory requirements for advanced practice nursing and chiropractic-medical collaboration.
• Privacy and confidentiality: We handle weight measurements, laboratory values, and sensitive clinical information with strict HIPAA compliance and protect it from unauthorized access.
• Documentation rigor: Every clinical note must reflect medical necessity, accurately document the patient’s status and the rationale for clinical decisions, and support the billing code assigned to the encounter.
• Conflict of interest transparency: Fully disclose any financial arrangements with supplement companies, pharmacy benefit managers, or device vendors to patients.

Putting It All Together: A Patient Journey Through Integrative Obesity Care

To illustrate how all of these components come together in real clinical practice, consider the following representative patient journey:

A 52-year-old woman presents at Injury Medical Clinic PA on August 18, 2026, with a chief complaint of difficulty managing her weight despite multiple prior attempts. Her history includes class II obesity (BMI 37.8), poorly controlled type 2 diabetes (most recent HbA1c 8.4%), hypertension managed with lisinopril, diagnosed obstructive sleep apnea on CPAP (incompletely adherent), and chronic low back pain rated 6/10 that severely limits her ability to walk for more than 10 minutes.

Dr. Cardenas’s Medical Evaluation

Dr. Cardenas conducts a comprehensive internal medicine evaluation, reviews the patient’s medication list, identifies that her current sulfonylurea is contributing to weight gain and causing intermittent hypoglycemia, and orders a comprehensive laboratory panel. Findings include severe insulin resistance (HOMA-IR 8.4), low Free T3 with normal TSH suggesting impaired T4-to-T3 conversion, severe vitamin D deficiency (18 ng/mL), and elevated hsCRP (5.2 mg/L). Dr. Cardenas adjusts the diabetes regimen, discontinuing the sulfonylurea and initiating semaglutide under careful monitoring, and adjusts hypertension management.

My Chiropractic and Functional Medicine Evaluation

My assessment reveals marked lumbar hyperlordosis, bilateral hip flexor shortening, gluteal inhibition, restricted lumbar range of motion, and L4-L5 segmental dysfunction generating significant nociceptive input. Functional movement assessment shows compensatory lateral trunk shift during single-leg stance and reduced bilateral ankle dorsiflexion. We establish a chiropractic and rehabilitation plan: twice-weekly lumbar manipulation and mobilization, myofascial release targeting the thoracolumbar fascia and hip flexors, progressive core stabilization exercises, and a graded walking program beginning at 10 minutes per session.

My functional medicine plan includes: a Mediterranean-style dietary protocol with a protein target of 120 grams daily, high-dose omega-3 supplementation (3 grams EPA+DHA daily), vitamin D3 5,000 IU daily with vitamin K2, magnesium glycinate 400 mg nightly, berberine 500 mg three times daily with meals, a high-potency probiotic for gut microbiome restoration, and CPAP adherence coaching coordinated with Dr. Cardenas.

The Six-Month Journey

Over the following six months, this patient attends weekly chiropractic sessions during months one and two (transitioning to biweekly then monthly as pain resolves), monthly medical follow-ups with Dr. Cardenas, biweekly behavioral counseling sessions with our health coach covering nutrition implementation, sleep hygiene, and stress management, and daily weight monitoring via her RPM smart scale.

At her six-month review, her outcomes include:

• Weight loss of 22 pounds (11.6% of initial body weight)
• HbA1c reduction from 8.4% to 6.8%
• Blood pressure well controlled on current medication
• Low back pain reduced from 6/10 to 1.5/10, with walking distance increased to 45 minutes per session
• Vitamin D normalized to 58 ng/mL
• hsCRP reduced to 1.4 mg/L
• CPAP adherence improved to 6.2 hours per night (from 3.1 hours at baseline)
• Quality of life significantly improved, with the patient reporting meaningful re-engagement in activities she had abandoned due to pain.

This outcome is possible only through an integrative, coordinated, evidence-based team approach. No single intervention achieved this; the convergence of medical management, chiropractic pain relief and rehabilitation, functional medicine root cause treatment, behavioral counseling, remote monitoring, and the dignity-affirming clinical culture of our practice all contributed.

Frequently Asked Questions

Do I need to choose one diet forever?

Absolutely not. We personalize and refine dietary recommendations based on your progress, lab results, food preferences, cultural traditions, and life context. The goal is to find a sustainable, anti-inflammatory dietary pattern that works for your biology and your life, not to impose a rigid dietary ideology.

Can chiropractic care help with weight management?

Indirectly but meaningfully, yes. By reducing pain and improving movement capacity, chiropractic care directly supports the physical activity pillar of obesity management, which is essential for maintaining weight loss, preserving lean muscle mass, and improving insulin sensitivity. Chiropractic care also modulates the autonomic nervous system in ways that may improve sleep quality, reduce cortisol, and support metabolic balance.

What if I cannot come every week?

We optimize your care schedule to fit your life and use telehealth for visits that don’t require a physical examination. We prioritize higher-frequency contact in the early phases of treatment, when establishing habits and momentum is most critical, and taper frequency as your plan stabilizes and becomes self-sustaining.

Do I need medications?

Not always, but when the biology of obesity is actively working against your best efforts, medications provide a necessary physiological counterweight that is no different in principle from using medication to manage any other chronic disease with a strong biological driver. We make these decisions together, transparently, with full informed consent, and under Dr. Cardenas’s medical oversight.

How do I know if I am making progress?

We track a comprehensive set of outcomes, including pain scores, functional capacity, metabolic markers, sleep quality, and weight trends, and we share this data with you at every visit. Progress in obesity care often manifests first as improved energy, reduced pain, better sleep, and improved metabolic markers, sometimes weeks before the scale moves significantly. We celebrate all of these wins because they represent the real goal of our work together: improved health, function, and quality of life.

Continuous Quality Improvement: How We Evolve Our Care

Our practice maintains a systematic approach to monitoring and improving the quality of obesity care we deliver:

• Access metrics: Wait times for new patient appointments, no-show rates, time from referral to first visit
• Clinical outcome metrics: HbA1c reduction, blood pressure control, pain and function scores, CPAP adherence, weight loss percentage at 3, 6, and 12 months
• Patient experience metrics: Patient-reported measures of dignity, respect, communication quality, and comfort, collected through validated surveys and anonymous feedback mechanisms
• Equity metrics: Treatment uptake and outcome data stratified by socioeconomic status, language preference, insurance status, and racial or ethnic identity, to identify and address disparities
• Coding and billing accuracy: Regular internal audits to ensure obesity E codes and Z codes are consistently paired, time documentation supports billed codes, and documentation accurately reflects medical necessity.

We iterate our protocols based on this data, patient feedback, and emerging clinical evidence, with quarterly team reviews to identify opportunities for improvement.

Conclusion: Integrative, Respectful, Evidence-Based Obesity Care Across the Lifespan

Obesity demands our best clinical thinking, our deepest compassion, and our willingness to build care systems that match the complexity and chronicity of the disease. As I reflect on the decades I have spent treating patients with obesity at Injury Medical Clinic PA, the clearest lesson I can offer is this: the patients who do best are the ones who have been treated with dignity, supported with evidence-based care across multiple clinical dimensions, and given the consistent, frequent touchpoints that chronic disease management requires.

The model I have described in this post, built around the integrative collaboration of Dr. Maria Guadalupe Cardenas’s internal medicine expertise and my chiropractic, functional medicine, and advanced practice nursing capabilities, with support from a multidisciplinary team of dietitians, health coaches, rehabilitation specialists, and behavioral health providers, is not a theoretical ideal. It is the daily reality of our practice in El Paso, Texas.

The physiological underpinnings are clear: obesity is a neuroendocrine, metabolic, inflammatory, autonomic, and musculoskeletal disease, and it demands interventions that address all these dimensions. The evidence supports the approach: from the STEP and SURMOUNT trials documenting the transformative power of GLP-1 receptor agonists, to the Look AHEAD trial validating intensive lifestyle intervention, to the Rubinstein et al. meta-analysis supporting spinal manipulation for low back pain, to the functional medicine evidence for gut microbiome restoration and micronutrient repletion, the science validates what we do.

The administrative infrastructure supports it too: with accurate ICD-10 coding using paired E codes and Z codes, time-based billing documentation that captures the full scope of our clinical effort, and specialized billing pathways through IBT, CCM, RPM, and preventive counseling codes, it is possible to build a financially sustainable practice that delivers the frequency and depth of care that patients with this chronic disease deserve.

What I ask of every clinician reading this post is simple: treat obesity as the chronic disease it is. Build the workflows. Train your team in dignity-affirming communication. Code accurately. Follow up frequently. And remember that every patient who walks through your door carrying both excess weight and the accumulated burden of a lifetime of stigma deserves to be seen, respected, and cared for as the whole, complex, extraordinary human being they are.

References

• American Gastroenterological Association. (2022). AGA clinical practice guidelines on pharmacological interventions for adults with obesity. Gastroenterology, 163(5), 1198-1212. doi.org/10.1053/j.gastro.2022.07.074
• Apovian, C. M., Aronne, L. J., Bessesen, D. H., McDonnell, M. E., Murad, M. H., Powell, U., & Ryan, D. H. (2015). Pharmacological management of obesity: An Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism, 100(2), 342-362. doi.org/10.1210/jc.2014-3415
• Beidelschies, M., Alejandro-Rodriguez, M., Ji, X., Bhatt, D., Husni, M. E., & Rothberg, M. B. (2019). Association of the functional medicine model of care with patient-reported health-related quality-of-life outcomes. JAMA Network Open, 2(10), e1914017. doi.org/10.1001/jamanetworkopen.2019.14017
• Cawley, J., Biener, A., Meyerhoefer, C., Ding, Y., Zvenyach, T., Smolarz, B. G., & Ramasamy, A. (2021). Direct medical costs of obesity in the United States and the most populous states. Journal of Managed Care and Specialty Pharmacy, 27(3), 354-366. doi.org/10.1016/j.jval.2021.03.019
• Estruch, R., Ros, E., Salas-Salvado, J., Covas, M. I., Corella, D., Aros, F., Gomez-Gracia, E., Ruiz-Gutierrez, V., Fiol, M., Lapetra, J., Lamuela-Raventos, R. M., Serra-Majem, L., Pinto, X., Basora, J., Munoz, M. A., Sorli, J. V., Martinez, J. A., & Martinez-Gonzalez, M. A. (2013). Primary prevention of cardiovascular disease with a Mediterranean diet. New England Journal of Medicine, 368(14), 1279-1290. doi.org/10.1056/NEJMoa1200303
• Gardner, C. D., Trepanowski, J. F., Del Gobbo, L. C., Hauser, M. E., Rigdon, J., Ioannidis, J. P. A., Desai, M., & King, A. C. (2018). Effect of low-fat vs low-carbohydrate diet on weight loss in overweight adults. JAMA, 319(7), 667-679. doi.org/10.1001/jama.2018.0245
• Garvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016). American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocrine Practice, 22(Suppl 3), 1-203. doi.org/10.4158/EP161365.GL
• Gearhardt, A. N., Schulte, E. M., & Hebebrand, J. (2016). Is “food addiction” a valid and useful concept? Obesity Reviews, 17(S1), 19-28. doi.org/10.1111/obr.12370
• Hall, K. D., & Kahan, S. (2018). Maintenance of lost weight and long-term management of obesity. Medical Clinics of North America, 102(1), 183-197. doi.org/10.1016/j.mcna.2017.08.012
• Hewagalamulage, S. D., Lee, T. K., Clarke, I. J., & Henry, B. A. (2016). Stress, cortisol, and obesity: A role for cortisol responsiveness in identifying individuals prone to obesity. Domestic Animal Endocrinology, 56, S112-S120. doi.org/10.1016/j.domaniend.2016.03.004
• Hruby, A., & Hu, F. B. (2015). The epidemiology of obesity: A big picture. PharmacoEconomics, 33(7), 673-689. doi.org/10.1007/s40273-014-0243-x
• Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., & Stefanski, A. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-216. doi.org/10.1056/NEJMoa2206038
• Jensen, M. D., Ryan, D. H., Apovian, C. M., Ard, J. D., Comuzzie, A. G., Donato, K. A., Hu, F. B., Hubbard, V. S., Jakicic, J. M., Kushner, R. F., Loria, C. M., Millen, B. E., Nonas, C. A., Pi-Sunyer, F. X., Stevens, J., Stevens, V. J., Wadden, T. A., Wolfe, B. M., & Yanovski, S. Z. (2014). 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults. Circulation, 129(25 Suppl 2), S102-S138. doi.org/10.1161/01.cir.0000437739.71477.ee
• Kahan, S., & Manson, J. E. (2019). Obesity treatment, beyond the guidelines: Practical suggestions for clinical practice. JAMA, 321(14), 1349-1350. doi.org/10.1001/jama.2019.6509
• Leidy, H. J., Clifton, P. M., Astrup, A., Wycherley, T. P., Westerterp-Plantenga, M. S., Luscombe-Marsh, N. D., Woods, S. C., & Mattes, R. D. (2015). The role of protein in weight loss and maintenance. American Journal of Clinical Nutrition, 101(6), 1320S-1329S. doi.org/10.3945/ajcn.114.084038
• Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., Lingvay, I., Oral, T. K., Michelsen, M. M., Plutzky, J., Tornoe, C. W., & Ryan, D. H. (2023). Semaglutide and cardiovascular outcomes in obesity without diabetes. New England Journal of Medicine, 389(24), 2221-2232. doi.org/10.1056/NEJMoa2307563
• Look AHEAD Research Group. (2013). Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. New England Journal of Medicine, 369(2), 145-154. doi.org/10.1056/NEJMoa1212914
• MacLean, P. S., Bergouignan, A., Cornier, M. A., & Jackman, M. R. (2015). Biology’s response to dieting: The impetus for weight regain. Obesity, 23(2), 247-261. doi.org/10.1002/oby.20966
• Messier, S. P., Gutekunst, D. J., Davis, C., & DeVita, P. (2005). Weight loss reduces knee-joint loads in overweight and obese older adults with knee osteoarthritis. Arthritis and Rheumatism, 52(7), 2026-2032. doi.org/10.1002/art.21139
• Obesity Medicine Association. (2022). Adult obesity algorithm. Obesity Medicine Association. Open access.
• Petersen, A. M. W., & Pedersen, B. K. (2005). The anti-inflammatory effect of exercise. Journal of Applied Physiology, 98(4), 1154-1162. doi.org/10.1152/japplphysiol.00164.2004
• Phelan, S. M., Burgess, D. J., Yeazel, M. W., Hellerstedt, W. L., Griffin, J. M., & van Ryn, M. (2015). Impact of weight bias and stigma on quality of care and outcomes for patients with obesity. Obesity Reviews, 16(4), 319-326. doi.org/10.1111/obr.12266
• Puhl, R. M., & Heuer, C. A. (2010). Obesity stigma: Important considerations for public health. American Journal of Public Health, 100(6), 1019-1028. doi.org/10.2105/AJPH.2009.159491
• Richter, E. A., & Hargreaves, M. (2013). Exercise, GLUT4, and skeletal muscle glucose uptake. Physiological Reviews, 93(3), 993-1017. doi.org/10.1152/physrev.00038.2012
• Roy, R. A., Boucher, J. P., & Comtois, A. S. (2009). Heart rate variability modulation after spinal manipulation in a healthy male subject. Journal of the Canadian Chiropractic Association, 53(4), 275-282.
• Rubinstein, S. M., de Zoete, A., van Middelkoop, M., Assendelft, W. J. J., de Boer, M. R., & van Tulder, M. W. (2019). Benefits and harms of spinal manipulative therapy for the treatment of chronic low back pain: Systematic review and meta-analysis of randomized controlled trials. BMJ, 364, l689. doi.org/10.1136/bmj.l689
• Sutton, E. F., Beyl, R., Early, K. S., Cefalu, W. T., Ravussin, E., & Peterson, C. M. (2018). Early time-restricted feeding improves insulin sensitivity, blood pressure, and oxidative stress even without weight loss in men with prediabetes. Cell Metabolism, 27(6), 1212-1221.e3. doi.org/10.1016/j.cmet.2018.04.010
• Tomiyama, A. J., Carr, D., Granberg, E. M., Major, B., Robinson, E., Sutin, A. R., & Brewis, A. (2014). How and why weight stigma drives the obesity “epidemic” and harms health. BMC Medicine, 16(1), 123. doi.org/10.1186/s12916-018-1116-5
• Wadden, T. A., Tronieri, J. S., & Butryn, M. L. (2020). Lifestyle modification approaches for the treatment of obesity in adults. American Psychologist, 75(2), 235-251. doi.org/10.1037/amp0000517
• Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. doi.org/10.1056/NEJMoa2032183
• Yeo, G. S. H. (2022). Genetics of obesity: What genetic association studies have taught us about obesity. Journal of Internal Medicine, 291(4), 401-412. doi.org/10.1111/joim.13438
• Zmora, N., Suez, J., & Elinav, E. (2019). You are what you eat: Diet, health and the gut microbiota. Nature Reviews Gastroenterology and Hepatology, 16(1), 35-56. doi.org/10.1038/s41575-018-0061-2

Dr. Alex Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST, practices at Injury Medical Clinic PA (Mission Plaza Injury Medical Clinic) in El Paso, Texas. His clinical observations and educational resources are available at HealthCoach. clinic. Connect with Dr. Jimenez on LinkedIn.

Dr. Maria Guadalupe Cardenas, MD (Board Certified in Internal Medicine, NPI #1164426749, Texas MD License #J2933) serves as Medical Director and Collaborative Physician at Injury Medical Clinic PA, bringing over 40 years of internist experience to our integrative multidisciplinary team.

SEO Tags: obesity care, integrative obesity treatment, chiropractic and obesity, Dr. Alex Jimenez, Dr. Maria Guadalupe Cardenas MD, Injury Medical Clinic El Paso, Mission Plaza Injury Medical Clinic, multidisciplinary obesity program, internal medicine medical director, GLP-1 receptor agonists, semaglutide weight loss, tirzepatide obesity, anti-obesity medications, functional medicine obesity, obesity ICD-10 coding 2024, obesity E codes Z codes, obesity billing and coding, time-based billing obesity, medical decision making obesity, intensive behavioral therapy obesity, IBT G0447, chronic care management CCM, remote patient monitoring RPM obesity, preventative counseling obesity, pediatric obesity coding, BMI classification, obesity chronic disease management, obesity comorbidities, obesity weight stigma, person-first language obesity, stigma-free obesity care, people-first language, weight bias healthcare, integrative chiropractic care, spinal manipulation metabolic health, autonomic nervous system obesity, HPA axis cortisol obesity, leptin resistance, ghrelin obesity, insulin resistance, HOMA-IR, gut microbiome obesity, adipokines obesity, visceral adiposity, Mediterranean diet obesity, anti-inflammatory diet obesity, protein and weight loss, time-restricted eating, resistance training obesity, physical activity obesity, obesity musculoskeletal pain, knee osteoarthritis obesity, low back pain obesity, chiropractic spinal manipulation, heart rate variability chiropractic, functional rehabilitation obesity, obesity personal injury care, obesity cardiovascular disease, obesity type 2 diabetes, NAFLD obesity, obstructive sleep apnea obesity, obesity pharmacotherapy, bariatric surgery, obesity telehealth, remote patient monitoring obesity, obesity social determinants health, culturally competent obesity care, El Paso obesity clinic, Texas obesity medicine, obesity practice management, obesity six-month care plan, obesity follow-up frequency, Look AHEAD trial, PREDIMED trial, STEP trial semaglutide, SURMOUNT trial tirzepatide, obesity evidence-based guidelines, OMA obesity algorithm, AACE obesity guidelines, AGA obesity pharmacotherapy, Endocrine Society obesity medications